[Federal Register Volume 91, Number 51 (Tuesday, March 17, 2026)]
[Proposed Rules]
[Pages 12700-12736]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2026-05167]


=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 63

[EPA-HQ-OAR-2019-0178; FRL-7055.1-01-OAR]
RIN 2060-AW79


National Emission Standards for Hazardous Air Pollutants: 
Ethylene Oxide Emissions Standards for Sterilization Facilities 
Residual Risk and Technology Review Reconsideration

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule; reconsideration of final rule.

-----------------------------------------------------------------------

SUMMARY: On April 5, 2024, the U.S. Environmental Protection Agency 
(EPA) published the National Emission Standards for Hazardous Air 
Pollutants (NESHAP): Ethylene Oxide Emissions Standards for 
Sterilization Facilities Residual Risk and Technology Review (2024 
Final Rule). The 2024 Final Rule revised the Commercial Sterilization 
Facilities NESHAP based on a residual risk and technology review (RTR) 
pursuant to the Clean Air Act (CAA) sections. On March 12, 2025, the 
EPA announced that it was reconsidering the 2024 Final Rule. Based on 
its reconsideration of the RTR in the 2024 Final Rule, the EPA is 
proposing to amend the Commercial Sterilization Facilities NESHAP. The 
amendments would rescind the risk based standards, revise the standard 
for new aeration room vents that resulted from the technology review, 
revise the compliance demonstration requirements, and rescind a 
requirement related to permanent total enclosure (PTE). This proposal 
also includes technical corrections and clarifications to the 
Commercial Sterilization Facilities NESHAP and Performance 
Specification 19 to address erroneous cross-references, omissions of 
text, and typographical errors in the regulatory text that the EPA has 
identified after publication of the 2024 Final Rule.

DATES: Comments must be received on or before May 1, 2026. Under the 
Paperwork Reduction Act (PRA), comments on the information collection 
provisions are best assured of consideration if the Office of 
Management and Budget (OMB) receives a copy of your comments on or 
before April 16, 2026.
    Public hearing: The EPA will hold a virtual public hearing on April 
1, 2026. Please refer to the SUPPLEMENTARY INFORMATION section for 
information on registering for the public hearing.

[[Page 12701]]


ADDRESSES: You may send comments, identified by Docket ID No. EPA-HQ-
OAR-2019-0178, by any of the following methods:
     Federal eRulemaking Portal: https://www.regulations.gov/ 
(our preferred method). Follow the online instructions for submitting 
comments.
     Email: [email protected]. Include Docket ID No. EPA-
HQ-OAR-2019-0178 in the subject line of the message.
     Fax: (202) 566-9744. Attention Docket ID No. EPA-HQ-OAR-
2019-0178.
     Mail: U.S. Environmental Protection Agency, EPA Docket 
Center, Docket ID No. EPA-HQ-OAR-2019-0178, Mail Code 28221T, 1200 
Pennsylvania Avenue NW, Washington, DC 20460.
     Hand/Courier Delivery: EPA Docket Center, WJC West 
Building, Room 3334, 1301 Constitution Avenue NW, Washington, DC 20004. 
The Docket Center's hours of operation are 8:30 a.m.-4:30 p.m., Monday-
Friday (except federal holidays).
    Instructions: All submissions received must include the Docket ID 
No. for this rulemaking. Comments received may be posted without change 
to https://www.regulations.gov/, including any personal information 
provided. For detailed instructions on sending comments and additional 
information on the rulemaking process, see the SUPPLEMENTARY 
INFORMATION section of this document.

FOR FURTHER INFORMATION CONTACT: For questions about this proposed 
action, contact U.S. EPA, Attn: Brian Langloss, Mail Drop: D243-04, 109 
T.W. Alexander Drive, P.O. Box 12055, Research Triangle Park, North 
Carolina 27711; telephone number: (919) 541-0675; and email address: 
[email protected].

SUPPLEMENTARY INFORMATION: 
    Participation in virtual public hearing. The hearing will be held 
via virtual platform on April 1, 2026. The EPA may close a session 15 
minutes after the last pre-registered speaker has testified if there 
are no additional speakers. The EPA will announce further details at 
https://www.epa.gov/stationary-sources-air-pollution/ethylene-oxide-emissions-standards-sterilization-facilities.
    The EPA will begin pre-registering speakers for the hearing no 
later than 1 business day after a request has been received. To 
register to speak at the virtual hearing, please use the online 
registration form available at https://www.epa.gov/stationary-sources-air-pollution/ethylene-oxide-emissions-standards-sterilization-facilities or contact the public hearing team at (888) 372-8699 or by 
email at [email protected]. The last day to pre-register to 
speak at the hearing will be March 30, 2026. Prior to the hearing, the 
EPA will post a general agenda that will list pre-registered speakers 
at: https://www.epa.gov/stationary-sources-air-pollution/ethylene-oxide-emissions-standards-sterilization-facilities.
    The EPA will make every effort to follow the schedule as closely as 
possible on the day of the hearing; however, please plan for the 
hearings to run either ahead of schedule or behind schedule.
    Each commenter will have 4 minutes to provide oral testimony. The 
EPA encourages commenters to submit a copy of their oral testimony as 
written comments electronically to the rulemaking docket.
    The EPA may ask clarifying questions during the oral presentations 
but will not respond to the presentations at that time. Written 
statements and supporting information submitted during the comment 
period will be considered with the same weight as oral testimony and 
supporting information presented at the public hearing.
    Please note that any updates made to any aspect of the hearing will 
be posted online at https://www.epa.gov/stationary-sources-air-pollution/ethylene-oxide-emissions-standards-sterilization-facilities. 
While the EPA expects the hearing to go forward as set forth above, 
please monitor our website or contact the public hearing team at (888) 
372-8699 or by email at [email protected] to determine if there 
are any updates. The EPA does not intend to publish a document in the 
Federal Register announcing updates.
    If you require the services of a translator or special 
accommodation such as audio description, please pre-register for the 
hearing with the public hearing team and describe your needs by March 
24, 2026. The EPA may not be able to arrange accommodations without 
advanced notice.
    Docket. The EPA has established a docket for this action under 
Docket ID No. EPA-HQ-OAR-2019-0178. All documents in the docket are 
listed in https://www.regulations.gov/. Although listed, some 
information is not publicly available, e.g., Confidential Business 
Information (CBI) or other information whose disclosure is restricted 
by statute. Certain other material, such as copyrighted material, is 
not placed on the internet and will be publicly available only as pdf 
versions that can only be accessed on the EPA computers in the docket 
office reading room. Certain databases and physical items cannot be 
downloaded from the docket but may be requested by contacting the 
docket office at 202-566-1744. The docket office has up to 10 business 
days to respond to these requests. Except for such material, publicly 
available docket materials are available electronically at https://www.regulations.gov.
    Instructions. Direct your comments to Docket ID No. EPA-HQ-OAR-
2019-0178. The EPA's policy is that all comments received will be 
included in the public docket without change and may be made available 
online at https://www.regulations.gov/, including any personal 
information provided, unless the comment includes information claimed 
to be CBI or other information whose disclosure is restricted by 
statute. Do not submit electronically to https://www.regulations.gov/ 
any information that you consider to be CBI or other information whose 
disclosure is restricted by statute. This type of information should be 
submitted as discussed below.
    The EPA may publish any comment received to its public docket. 
Multimedia submissions (audio, video, etc.) must be accompanied by a 
written comment. The written comment is considered the official comment 
and should include discussion of all points you wish to make. The EPA 
will generally not consider comments or comment contents located 
outside of the primary submission (i.e., on the Web, cloud, or other 
file sharing system). For additional submission methods, the full EPA 
public comment policy, information about CBI or multimedia submissions, 
and general guidance on making effective comments, please visit https://www.epa.gov/dockets/commenting-epa-dockets.
    The https://www.regulations.gov/ website allows you to submit your 
comment anonymously, which means the EPA will not know your identity or 
contact information unless you provide it in the body of your comment. 
If you send an email comment directly to the EPA without going through 
https://www.regulations.gov/, your email address will be automatically 
captured and included as part of the comment that is placed in the 
public docket and made available on the internet. If you submit an 
electronic comment, the EPA recommends that you include your name and 
other contact information in the body of your comment and with any 
digital storage media you submit. If the EPA cannot read your comment 
due to technical difficulties and cannot contact you for clarification, 
the EPA may not

[[Page 12702]]

be able to consider your comment. Electronic files should not include 
special characters or any form of encryption and should be free of any 
defects or viruses. For additional information about the EPA's public 
docket, visit the EPA Docket Center homepage at https://www.epa.gov/dockets.
    Throughout this proposal, the EPA is soliciting comment on numerous 
aspects of the proposed rule. The EPA has indexed each comment 
solicitation with an identifier (e.g., ``Question 1, Question 2, . . .) 
to provide a consistent framework for effective and efficient provision 
of comments. Accordingly, we ask that commenters include the 
corresponding identifier when providing comments relevant to that 
comment solicitation. We ask that commenters include the identifier in 
either a heading, or within the text of each comment (e.g., ``In 
response to Question 1, . . .'') to make clear which comment 
solicitation is being addressed.
    Submitting CBI. Do not submit information containing CBI to the EPA 
through https://www.regulations.gov/. Clearly mark the part or all the 
information that you claim to be CBI. For CBI information on any 
digital storage media that you mail to the EPA, note the docket ID, 
mark the outside of the digital storage media as CBI, and identify 
electronically within the digital storage media the specific 
information that is claimed as CBI. In addition to one complete version 
of the comments that includes information claimed as CBI, you must 
submit a copy of the comments that does not contain the information 
claimed as CBI directly to the public docket through the procedures 
outlined in Instructions above. If you submit any digital storage media 
that does not contain CBI, mark the outside of the digital storage 
media clearly that it does not contain CBI and note the docket ID. 
Information not marked as CBI will be included in the public docket and 
the EPA's electronic public docket without prior notice. Information 
marked as CBI will not be disclosed except in accordance with 
procedures set forth in 40 Code of Federal Regulations (CFR) part 2.
    Our preferred method to receive CBI is for it to be transmitted 
electronically using email attachments, File Transfer Protocol (FTP), 
or other online file sharing services (e.g., Dropbox, OneDrive, Google 
Drive). Electronic submissions must be transmitted directly to the 
Office of Clean Air Programs (OCAP) CBI Office at the email address 
[email protected] and, as described above, should include clear CBI 
markings and note the docket ID. If assistance is needed with 
submitting large electronic files that exceed the file size limit for 
email attachments, and if you do not have your own file sharing 
service, please email [email protected] to request a file transfer 
link. If sending CBI information through the postal service, please 
send it to the following address: OCAP Document Control Officer (C404-
02), OCAP, U.S. Environmental Protection Agency, Research Triangle 
Park, North Carolina 27711, Attention Docket ID No. EPA-HQ-OAR-2019-
0178. The mailed CBI material should be double wrapped and clearly 
marked. Any CBI markings should not show through the outer envelope.
    Preamble acronyms and abbreviations. Throughout this preamble the 
use of ``we,'' ``us,'' or ``our'' is intended to refer to the EPA. We 
use multiple acronyms and terms in this preamble. While this list may 
not be exhaustive, to ease the reading of this preamble and for 
reference purposes, the EPA defines the following terms and acronyms 
here:

APCD air pollution control device
ARV aeration room vent
ASTM American Society for Testing and Materials
CAA Clean Air Act
CBI Confidential Business Information
CEMS continuous emission monitoring system
CEV chamber exhaust vent
CFR Code of Federal Regulations
CMS continuous monitoring system
EAV equivalent annualized values
EPA Environmental Protection Agency
EtO ethylene oxide
FTP File Transfer Protocol
FR Federal Register
HAP hazardous air pollutant
ICR information collection request
IRIS Integrated Risk Information System
NAICS North American Industry Classification System
NESHAP national emission standards for hazardous air pollutants
OCAP Office of Clean Air Programs
OMB Office of Management and Budget
ppm parts per million
PRA Paperwork Reduction Act
PTE permanent total enclosure
PS performance specification
PV present values
RFA Regulatory Flexibility Act
RGM Research Gas Mixture
RIA regulatory impact analysis
RTR risk and technology review
SCV sterilization chamber vent
SSM startup, shutdown, and malfunction
SWEL site wide emission limitation
TCEQ Texas Commission on Environmental Quality
tpy tons per year
VCS voluntary consensus standards

    Table of Contents. The information in this preamble is organized as 
follows:

I. General Information
    A. Executive Summary
    B. Does this action apply to me?
    C. Where can I get a copy of this document and other related 
information?
II. Background
    A. What is the statutory authority for this proposed action?
    B. What is the scope of this reconsideration proposal?
    C. What is this source category and how does the current NESHAP 
regulate its EtO emissions?
    D. What data collection activities were conducted to support 
this action?
    E. What other relevant background information is available?
III. Reconsideration and Other Issues, Proposed Changes and 
Rationale
    A. What changes are we proposing for the CAA section 112(f)(2) 
standards, and what is the rationale for those decisions?
    B. What changes are we proposing for the CAA section 112(d)(6) 
standards, and what is the rationale for those decisions?
    C. What changes are we proposing for initial and continual 
compliance with the emission reduction standards, and what is the 
rationale for those decisions?
    D. What changes are we proposing to PTE requirements, and what 
is the rationale for those actions?
    E. What technical corrections and amendments to the Commercial 
Sterilization Facilities NESHAP are we proposing, and what is the 
rationale for those actions?
    F. What technical corrections and amendments to Performance 
Specification 19 are we proposing, and what is the rationale for 
those actions?
    G. What compliance dates are we proposing, and what is the 
rationale for the proposed compliance dates?
IV. Severability
V. Summary of Cost, Environmental, and Economic Impacts
    A. What are the affected sources?
    B. What are the air quality impacts?
    C. What are the cost impacts?
    D. What are the economic impacts?
    E. What are the benefits?
    F. What analysis of children's environmental health did we 
conduct?
VI. Request for Comments
VII. Statutory and Executive Order Reviews
    A. Executive Order 12866: Regulatory Planning and Review and 
Executive Order 13563: Improving Regulation and Regulatory Review
    B. Executive Order 14192: Unleashing Prosperity Through 
Deregulation
    C. Paperwork Reduction Act (PRA)
    D. Regulatory Flexibility Act (RFA)
    E. Unfunded Mandates Reform Act (UMRA)
    F. Executive Order 13132: Federalism
    G. Executive Order 13175: Consultation and Coordination With 
Indian Tribal Governments
    H. Executive Order 13045: Protection of Children From 
Environmental Health Risks and Safety Risks
    I. Executive Order 13211: Actions Concerning Regulations That 
Significantly Affect Energy Supply, Distribution, or Use

[[Page 12703]]

    J. National Technology Transfer and Advancement Act (NTTAA)

I. General Information

A. Executive Summary

    In this reconsideration action, the EPA is proposing, after 
consultation with U.S. Department of Health and Human Services, to 
rescind or revise certain amendments made to the Commercial 
Sterilization Facilities NESHAP in the 2024 Final Rule to adhere to the 
best reading of the statute. The Agency first promulgated standards for 
this source category in 1994. Under CAA section 112(f)(2), the EPA was 
required to review the standards within eight years to identify and 
address residual risk to human health and the environment. Under CAA 
section 112(d)(6), the EPA is also required to review and revise the 
standards ``as necessary'' at least every eight years to address 
developments in practices, processes, and control technologies. In 
2006, the Agency discharged these obligations by completing the RTR for 
the Commercial Sterilization Facilities source category, finding that 
the existing standards adequately protected public health with an ample 
margin of safety and, separately, concluding that no further revisions 
were ``necessary'' at that time given the minimal emission reductions 
and high costs associated with available control strategies.
    In 2024, however, the EPA for the first time implemented an 
interpretation of CAA section 112(f)(2) that authorizes the Agency to 
conduct additional discretionary residual risk reviews (after 
completing the mandatory residual risk review within eight years of 
promulgating MACT standards) and impose risk-based standards pursuant 
to a second risk review. We reasoned in the 2024 Final Rule and related 
actions that the Agency possesses this authority because nothing in the 
statute expressly precludes discretionary residual risk reviews. Upon 
reconsideration, the EPA proposes that the interpretation as finalized 
in the 2024 Final Rule is inconsistent with the best reading of the 
statute. We ``possess only the authority that Congress has provided,'' 
\1\ and statutes have a ``single, best meaning'' that is `` `fixed at 
the time of enactment.' '' \2\ We propose that, read in context, CAA 
section 112(f)(2) explicitly authorizes a single residual risk review 
of the MACT standards within eight years, coupled with an express 
authority to review and revise the standards ``as necessary'' through a 
technology review at least every eight years under CAA section 
112(d)(6). This interpretation better reflects the structure of CAA 
section 112, which Congress deliberately designed with detailed 
implementation timelines and requirements that cannot be squared with 
the assertion of authority to revisit residual risk reviews on an ad 
hoc, category-by-category basis. We propose to rescind the section 
112(f)(2) standards imposed by the 2024 Final Rule on this basis, 
thereby returning the Commercial Sterilization Facilities source 
category to the generally applicable regulatory framework arising under 
section 112(d).
---------------------------------------------------------------------------

    \1\ NFIB v. DOL, 595 U.S. 109, 117 (2022).
    \2\ Loper Bright Enters. v. Raimondo, 603 U.S. 369, 400, 411 
(2024) (quoting Wis. Cent. Ltd. v. United States, 585 U.S. 274, 284 
(2018)).
---------------------------------------------------------------------------

    The EPA is also proposing relatively minor adjustments to the 
revised standards finalized in the 2024 Final Rule under CAA section 
112(d)(6). We propose to reduce the emission standard for new ARVs at 
facilities with EtO use of at least 10 tpy, which would result in a 
single standard for both new and existing ARVs. This has the benefit of 
allowing facilities to share infrastructure, streamline facility 
operations, and reflect common practices at facilities. Finally, we are 
proposing several technical corrections and clarifications to the 
regulatory text identified after publication of the 2024 Final Rule, 
including erroneous cross-references, omissions, and typographical 
errors.

B. Does this action apply to me?

    Table 1 of this preamble lists industrial categories potentially 
affected by this action. Table 1 is not intended to be exhaustive but 
rather provides a guide for readers regarding the entities that this 
proposed action is likely to affect. The proposed standards, once 
promulgated, will directly apply to the affected sources. Federal, 
state, local, and Tribal government entities would not be affected by 
this proposed action. As defined in the Initial List of Categories of 
Sources Under Section 112(c)(1) of the Clean Air Act Amendments of 1990 
and Documentation for Developing the Initial Source Category List, 
Final Report,\3\ the Commercial Sterilization Facilities source 
category includes any facility engaged in the use of EtO as a sterilant 
and fumigant following the production of various products (e.g., 
medical equipment and supplies) and in miscellaneous sterilization and 
fumigation operations at both major and area sources. These commercial 
sterilization facilities use EtO as a sterilant for heat- or moisture-
sensitive materials and as a fumigant to control microorganisms. 
Facilities may sterilize materials produced on site, or contract 
sterilizers may sterilize products manufactured by other companies.
---------------------------------------------------------------------------

    \3\ 57 FR 31576 (July 16, 1992) and EPA-450/3-91-030, July 1992, 
respectively.

---------------------------------------------------------------------------

[[Page 12704]]

[GRAPHIC] [TIFF OMITTED] TP17MR26.011

C. Where can I get a copy of this document and other related 
information?

    In addition to being available in the docket, an electronic copy of 
this action is available on the EPA website. Following signature by the 
EPA Administrator, the EPA will post a copy of this proposed action at 
https://www.epa.gov/stationary-sources-air-pollution/ethylene-oxide-emissions-standards-sterilization-facilities. Following publication in 
the Federal Register, the EPA will post the Federal Register version of 
the proposal and key technical documents on the same web page.
    A memorandum showing the rule edits that would be necessary to 
incorporate the changes to 40 CFR part 63, subpart O proposed in this 
action is available in the docket (Docket ID No. EPA-HQ-OAR-2019-0178). 
Following signature by the EPA Administrator, the EPA also will post a 
copy of this document to https://www.epa.gov/stationary-sources-air-pollution/ethylene-oxide-emissions-standards-sterilization-facilities.

II. Background

A. What is the statutory authority for this proposed action?

    The statutory authority for this action is provided by CAA section 
112, as amended.\4\ CAA section 112 establishes a multi-stage 
regulatory process to develop standards for emissions of HAP from 
stationary sources. Generally, the first stage involves establishing 
technology-based standards that reflect the maximum achievable control 
technology (MACT) or an appropriate alternative.\5\ The second stage 
involves evaluating those standards within eight years under CAA 
section 112(f)(2) to determine whether additional standards are needed 
to address any remaining risk associated with HAP emissions.\6\ This 
second stage is commonly referred to as the ``residual risk review.'' 
In addition to the residual risk review, CAA section 112(d)(6) also 
requires the EPA to review the standards every eight years and ``revise 
as necessary,'' taking into account ``developments in practices, 
processes, and control technologies.'' \7\ This review is commonly 
referred to as the ``technology review.''
---------------------------------------------------------------------------

    \4\ 42 U.S.C. 7412.
    \5\ 42 U.S.C. 7412(d)(1)-(3).
    \6\ 42 U.S.C. 7412(f)(2).
    \7\ 42 U.S.C. 7412(d)(6).
---------------------------------------------------------------------------

    In the first stage of the CAA section 112 standard-setting process, 
the EPA promulgates technology-based standards under CAA section 112(d) 
for categories of sources identified as emitting one or more of the HAP 
listed in CAA section 112(b). Sources of HAP emissions are either major 
sources or area sources, and CAA section 112 establishes different 
requirements for major source standards and area source standards. The 
requirements for major sources are the relevant requirements for the 
present rulemaking. ``Major sources'' are those that emit or have the 
potential to emit 10 tons per year (tpy) or more of a single HAP or 25 
tpy or more of any combination of HAP.\8\ For major sources, CAA 
section 112(d)(2) provides that the technology-based NESHAP must 
reflect the maximum degree of reduction in emissions of HAP achievable 
(after considering cost, energy requirements, and non-air quality 
health and environmental impacts). These standards are commonly 
referred to as MACT standards. CAA section 112(d)(3) also establishes a 
minimum control level for MACT standards, known as the MACT ``floor,'' 
which is based on emission controls achieved in practice by a certain 
percentage of the best performing sources. The EPA also considers 
control options that are more stringent than the floor. Standards more 
stringent than the floor are commonly referred to as ``beyond-the-
floor'' standards. The next stage in standard-setting focuses on 
identifying and addressing any remaining (i.e., ``residual'') risk 
within eight years pursuant to CAA section 112(f)(2) and concurrently 
conducting a technology review pursuant to CAA section 112(d)(6). This 
latter provision requires the EPA to review standards promulgated under 
CAA section 112 and revise them ``as necessary (taking into account 
developments in practices, processes, and control technologies)'' no 
less often than every eight years. In conducting this review, which we 
call the ``technology review,'' the EPA is not required to recalculate 
the MACT floors that were established in earlier rulemakings.\9\ The 
EPA considers cost in deciding whether to revise the standards pursuant 
to CAA section 112(d)(6).
---------------------------------------------------------------------------

    \8\ 42 U.S.C. 7412(a)(1).
    \9\ Ass'n of Battery Recyclers, Inc. v. EPA, 716 F.3d 667 (D.C. 
Cir. 2013); Natural Resources Def. Council (NRDC) v. EPA, 529 F.3d 
1077, 1084 (D.C. Cir. 2008).
---------------------------------------------------------------------------

    The proposed amendments in this action result from the EPA's 
reconsideration of certain aspects of the 2024 Final Rule, including 
the interpretation of CAA section 112(f)(2)

[[Page 12705]]

adopted in the 2024 Final Rule to justify imposing additional risk-
based standards rather than solely considering whether such standards 
were ``necessary'' under CAA section 112(d)(6). Specifically, the EPA 
took the position in the 2024 Final Rule (and again in two additional 
rules finalized the following month) that the Agency may, on a 
discretionary basis, utilize the risk-review process in CAA section 
112(f)(2) to promulgate additional risk-based standards for a source 
category that has already undergone a residual risk review after 
promulgation of MACT standards.\10\ As explained further below, the EPA 
now proposes to interpret CAA section 112(f)(2) as setting out a one-
time authority and obligation to assess the residual risk remaining for 
the source category at issue within eight years of promulgating MACT 
standards.
---------------------------------------------------------------------------

    \10\ See New Source Performance Standards for the Synthetic 
Organic Chemical Manufacturing Industry and National Emission 
Standards for Hazardous Air Pollutants for the Synthetic Organic 
Chemical Manufacturing Industry and Group I & II Polymers and Resins 
Industry, 89 FR 42932 (May 16, 2024) (finalizing NESHAP amendments 
for two source categories in same Federal Register notice). The 
Agency proposed to apply this interpretation to a third source 
category in a December 2024 proposed rule on which we have not yet 
taken final action. See Review of National Emission Standards for 
Hazardous Air Pollutants for Polyether Polyols Production Industry, 
89 FR 105986 (Dec. 27, 2024).
---------------------------------------------------------------------------

    Agencies have authority to reconsider prior policy and to revise, 
replace, or repeal prior actions to the extent permitted by the 
governing statute and supported by a reasoned explanation.\11\ This is 
true when, as is the case here, an agency reconsiders a prior action 
after a change in administration.\12\ As explained below, the EPA is 
proposing to repeal certain standards imposed in the 2024 Final Rule on 
the ground that the Agency erred in interpreting CAA section 112(f)(2) 
as authorizing the imposition of further rounds of risk-based standards 
in lieu of the ongoing authority and obligation at least every eight 
years to revise the standards ``as necessary'' under CAA section 
112(d)(6). We are also proposing revisions to certain additional 
standards promulgated in the 2024 Final Rule under CAA section 
112(d)(6). We propose that nothing in the relevant statutory language 
precludes or conditions the EPA's authority to repeal the CAA section 
112(f)(2) standards based on new conclusions about the best reading of 
the statute or the EPA's authority to further revise prior standards 
adopted under CAA section 112(d)(6).
---------------------------------------------------------------------------

    \11\ FDA v. Wages & White Lion Invs., L.L.C., 604 U.S. 542, 567 
(2025); FCC v. Fox Television Stations, Inc., 556 U.S. 502, 515 
(2009); Motor Vehicle Mfrs. Ass'n, Inc. v. State Farm Mutual Auto. 
Ins. Co., 463 U.S. 29, 42 (1983).
    \12\ See Nat'l Ass'n of Home Builders v. EPA, 682 F.3d 1032, 
1038, 1043 (D.C. Cir. 2012) (explaining that an agency's 
``reevaluation of which policy would be better in light of the 
facts'' is ``well within'' its discretion and that a change in 
administration is a ``perfectly reasonable basis for an executive 
agency's reappraisal of the costs and benefits of its programs and 
regulations'' (internal quotation marks omitted)).
---------------------------------------------------------------------------

    In doing so, the EPA acknowledges that this proposed action would, 
if finalized, change the position taken in the 2024 Final Rule with 
respect to CAA section 112(f)(2) and, at a more granular level, change 
several of the Agency's conclusions with respect to standards adopted 
in the 2024 Final Rule under CAA section 112(d)(6). The rationale for 
each of these changes is described in the relevant section of this 
document. We do not believe that the standards or supporting 
interpretations adopted in the 2024 Final Rule have generated 
significant and cognizable reliance interests, including because the 
standards have not yet gone fully into effect. With respect to 
questions of statutory interpretation, we do not believe any such 
reliance interests could support retaining an action that is 
inconsistent with the best reading of the statute. Nevertheless, we 
seek comment on whether the 2024 Final Rule and underlying 
interpretations have generated such reliance interests and, if so, how 
the EPA should consider them in any final action (Question 1).

B. What is the scope of the reconsideration proposal?

    On March 12, 2025, the EPA announced that it is reconsidering the 
2024 Final Rule.\13\ Subsequently, in a letter dated March 21, 2025, 
the EPA provided further details on the reconsideration, indicating 
that we would reexamine our authority and decision to undertake a 
second residual risk review pursuant to CAA section 112(f)(2), the 
standards promulgated pursuant to CAA section 112(d)(6), and the 
requirement to demonstrate compliance using a continuous emission 
monitoring system (CEMS).\14\ This action is consistent with Executive 
Order 14192 which promotes prudent financial management and alleviates 
unnecessary regulatory burdens.
---------------------------------------------------------------------------

    \13\ U.S. EPA, Trump EPA Announces Reconsideration of Air Rules 
Regulating American Energy, Manufacturing, Chemical Sectors 
(NESHAPs), (March 12, 2025) [Press Release].
    \14\ Letter from U.S. EPA to Ethylene Oxide Sterilization 
Association, (March 21, 2025), https://www.epa.gov/system/files/documents/2025-03/revised-epa-response-to-meibao-zhuang-eto-sterilizers-reconsideration.pdf.
---------------------------------------------------------------------------

    In this action, based on the EPA's reconsideration of the 2024 
Final Rule, we are proposing amendments to the Commercial Sterilization 
Facilities NESHAP. Specifically, the EPA is proposing to rescind the 
standards that were established under CAA section 112(f)(2), to amend 
the standard promulgated under section 112(d)(6) for new aeration room 
vents (ARVs) where EtO use is at least 10 tons per year (tpy), to amend 
the compliance demonstration requirements to allow facilities to choose 
between annual performance testing and parametric monitoring or 
operation of a CEMS, and to rescind the requirement that PTE be used to 
ensure complete capture of EtO. This proposal also includes technical 
corrections and clarifications to the Commercial Sterilization 
Facilities NESHAP and Performance Specification 19 (PS 19). Any other 
issues or any other provisions of the 2024 Final Rule not specifically 
addressed in this proposed rulemaking are not within the scope of this 
proposal, and the EPA reserves the right to respond to such comments as 
out of scope.

C. What is this source category and how does the current NESHAP 
regulate its EtO emissions?

1. Regulatory Background
    The Commercial Sterilization Facilities source category consists of 
major and area sources that use EtO to sterilize or fumigate materials, 
including medical equipment and supplies, certain spices, and other 
miscellaneous products and items. Generally speaking, these facilities 
use chambers or sealed pouches to disinfect materials through exposure 
to EtO gas at predetermined concentrations (including materials not 
amenable to other sterilization techniques, such as high temperatures), 
which is then evacuated from the chamber or pouch prior to retrieving 
the sterilized materials.\15\ Sources in this category provide 
essential sterilization services at scale for hospitals, clinics, and 
other medical locations that lack capacity to sterilize equipment at 
the volume and regularity required to maintain safe and efficient 
operations.
---------------------------------------------------------------------------

    \15\ For more information, see 88 FR 22796-97 (Apr. 13, 2023).
---------------------------------------------------------------------------

    The EPA promulgated the initial Commercial Sterilization Facilities 
NESHAP on December 6, 1994.\16\ The standards are codified at 40 CFR 
part 63, subpart O. The original 1994 rulemaking for this source 
category set standards for EtO emissions originating from three 
emission points: sterilization chamber vents (SCVs), ARVs, and chamber 
exhaust vents (CEVs). The SCV evacuates EtO from the sterilization

[[Page 12706]]

chamber following sterilization, fumigation, and any subsequent gas 
washes before the chamber door is opened. The ARV evacuates EtO-laden 
air from the aeration room or chamber that is used to facilitate off-
gassing of the sterile product and packaging. The CEV evacuates EtO-
laden air from the sterilization chamber after the chamber door is 
opened for product unloading following the completion of sterilization 
and associated gas washes.
---------------------------------------------------------------------------

    \16\ 59 FR 62585 (Dec. 6, 1994).
---------------------------------------------------------------------------

    In 2006, the EPA finalized the RTR for the Commercial Sterilization 
Facilities NESHAP under CAA section 112(f)(2) and CAA section 
112(d)(6), respectively.\17\ With respect to the residual risk review, 
we concluded that the MACT standards protected public health and the 
environment with an ample margin of safety by reducing maximum 
individual cancer risk, as well as chronic noncancer and acute risks, 
below the levels generally considered acceptable for purposes of CAA 
section 112(f)(2).\18\ With respect to the technology review, we 
concluded that additional standards ``would achieve, at best, minimal 
emission and risk reductions at a very high cost.'' \19\ No changes 
were made in the RTR to MACT standards given these findings. In 
responding to comments on the residual risk review, we explained that 
the Agency considered a California EPA cancer risk estimate as the best 
available estimate, for reasons including because it built upon our own 
1985 EtO health assessment. We noted that the Agency was working on an 
updated cancer assessment for EtO that was not yet complete.\20\ 
Finally, we disagreed with comments arguing that the residual risk 
review should ``account for reasonably foreseeable changes that could 
result in increased risk, such as new residences being built closer to 
the facility, or increases in actual emissions within the current 
permit limitations.'' Specifically, we stated that risk assessments 
need not consider such foreseeable changes because we ``have the 
authority to revisit (and revise, if necessary) any rulemaking if there 
is sufficient evidence'' for doing so, citing to CAA section 301.\21\
---------------------------------------------------------------------------

    \17\ 71 FR 17712 (Apr. 7, 2006).
    \18\ Id. at 17713.
    \19\ Id. at 17714.
    \20\ Id. at 17715-16.
    \21\ Id. (citing 42 U.S.C. 7601).
---------------------------------------------------------------------------

    In 2022, several environmental groups filed a mandatory duty suit 
against the EPA under CAA section 304(a)(2).\22\ The groups alleged 
that the EPA failed to perform its non-discretionary duty under CAA 
section 112(d)(6) to review, and as necessary revise, the Commercial 
Sterilization Facilities NESHAP every eight years. The parties resolved 
the lawsuit through a consent decree, which required the EPA to sign a 
final rule completing the CAA section 112(d)(6) review by March 1, 
2024. The consent decree did not speak to or reference CAA section 
112(f)(2).
---------------------------------------------------------------------------

    \22\ Cal. Communities Against Toxics v. Regan, No. 1:22-cv-03724 
(D.D.C).
---------------------------------------------------------------------------

2. 2024 Final Rule
    In April 2023, the EPA proposed ``decisions concerning'' the 
completed RTR, including certain amendments resulting from a second 
residual risk review for EtO and additional amendments resulting from a 
technology review.\23\ With respect to the second residual risk review, 
the Agency proposed to rely on the Integrated Risk Information System 
(IRIS) value for EtO issued by the EPA in December 2016 \24\ and, in 
``deciding whether to conduct a second residual risk review,'' 
considered ``the advantages of EtO reductions and the distribution of 
those reductions consistent with the clear goal of CAA section 
112(f)(2) to protect the most exposed and susceptible populations, 
which in this case include communities with EJ [environmental justice] 
concerns.'' \25\ We acknowledged at the time that ``CAA section 
112(f)(2) requires only a one-time risk review, which is to be 
conducted within eight years of the date the initial standards are 
promulgated.'' However, we asserted that the provision ``does not limit 
the EPA's discretion or authority to conduct another risk review'' and 
identified a ``discretionary authority to conduct another CAA section 
112(f)(2) analysis'' at will separate and apart from the review and 
revision authority provided in CAA section 112(d)(6).\26\
---------------------------------------------------------------------------

    \23\ 88 FR 22790 (Apr. 13, 2023).
    \24\ Evaluation of the Inhalation Carcinogenicity of Ethylene 
Oxide, December 2016, EPA/635/R-16/350Fc.
    \25\ Id. at 22793.
    \26\ Id. at 22794.
---------------------------------------------------------------------------

    The 2024 Final Rule amended 40 CFR part 63, subpart O pursuant to 
CAA sections 112(d)(2) and (3), 112(d)(5), 112(d)(6), and 
112(f)(2).\27\ That action established standards for unregulated 
sources of emissions (CEV,\28\ Group 1 \29\ and Group 2 \30\ room air 
emissions) under the authority of CAA section 112(d)(2) and (3) for 
major sources and CAA section 112(d)(5) for area sources. The EPA also 
revised the existing standards in response to a technology review under 
CAA section 112(d)(6). The EPA for the first time implemented an 
interpretation that CAA section 112(f)(2) authorizes the imposition of 
new standards based on additional discretionary residual risk reviews 
and finalized new risk-based standards after conducting a second risk 
review based largely on the 2016 EtO IRIS value. The 2024 Final Rule 
also finalized other changes to the NESHAP, including adding 
requirements and clarifications for periods of startup, shutdown, and 
malfunction (SSM); requiring the use of CEMS to demonstrate compliance 
for facilities where EtO use is at least 100 pounds per year (lb/yr); 
adding provisions for electronic reporting of performance test results 
and reports, performance evaluation reports, and compliance reports; 
and other minor editorial and technical changes.
---------------------------------------------------------------------------

    \27\ 89 FR 24090 (Apr. 5, 2024).
    \28\ The standards for CEVs were originally promulgated on 
December 6, 1994. Following promulgation of the rule, the EPA 
suspended certain compliance deadlines and ultimately removed the 
standards for CEVs due to safety concerns. In the late 1990s, there 
were multiple explosions at EtO commercial sterilization facilities 
using oxidizers to control emissions from CEVs. It was determined 
that the primary contributing issue leading to the explosions was 
that EtO concentrations were above a safe level (i.e., above the 
lower explosive limit (LEL)) within the CEV gas streams. The EPA 
could not conclude at the time that the CEVs could be safely 
controlled, so the standards for CEVs were removed on November 2, 
2001 (66 FR 55583).
    \29\ Group 1 room air emissions mean emissions from indoor EtO 
storage, EtO dispensing, vacuum pump operations, and pre-aeration 
handling of sterilized material.
    \30\ Group 2 room air emissions mean emissions from post-
aeration handling of sterilized material.
---------------------------------------------------------------------------

    Table 2 shows a summary of the 2024 emission standards for 
commercial sterilizers facilities in 40 CFR part 63, subpart O. 
Footnote 1 of Table 2 shows the standards subject to reconsideration.
BILLING CODE 6560-50-P

[[Page 12707]]

[GRAPHIC] [TIFF OMITTED] TP17MR26.012


[[Page 12708]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.013

BILLING CODE 6560-50-C
    For more information on the commercial sterilization industry and 
the 2024 standards under 40 CFR part 63, subpart O see the 2024 Final 
Rule preamble.\31\
---------------------------------------------------------------------------

    \31\ 89 FR 24090 (Apr. 5, 2024).
---------------------------------------------------------------------------

D. What data collection activities were conducted to support this 
action?

    The EPA used data collected during the rulemaking for the 2024 
Final Rule for this reconsideration. The EPA began with the facility 
list used during the 2024 Final Rule. For details on the data collected 
for the 2024 Final Rule, see section II.C of the 2023 proposal 
preamble.\32\ Since the promulgation of the 2024 Final Rule, the EPA 
identified two facilities that have opened and one facility that has 
decommissioned its use of EtO, resulting in a final facility list of 89 
commercial sterilization facilities. A complete list of known 
commercial sterilization facilities is available in the document titled 
2024 Facility List, which is available in the docket for this 
rulemaking.
---------------------------------------------------------------------------

    \32\ 88 FR 22790 (Apr. 13, 2023).
---------------------------------------------------------------------------

    In addition to the information obtained during the investigation 
for the 2024 Final Rule, the EPA held meetings with industry and trade 
association representatives to discuss the 2024 Final Rule and the 
implementation issues, unintended impacts, and challenges that have 
resulted from the rule. Summaries of these meetings can be found in the 
docket for this action (Docket ID No. EPA-HQ-OAR-2019-0178).

E. What other relevant background information is available?

    On June 5, 2024, the Ethylene Oxide Sterilization Association 
(EOSA) and various environmental and community groups, including 
California Communities Against Toxics, Clean Power Lake County, 
Comit[eacute] Di[aacute]logo Ambiental, Rio Grande International Study 
Center, Sierra Club, and the Union of Concerned Scientists, brought 
separate judicial challenges to the 2024 Final Rule. The cases were 
consolidated and are currently being held in abeyance pending the EPA's 
reconsideration of the rule.
    On July 17, 2025, President Trump signed the Proclamation, 
``Regulatory Relief for Certain Stationary Sources to Promote American 
Security With Respect to Sterile Medical Equipment''

[[Page 12709]]

(90 FR 34747, July 23, 2025).\33\ This Proclamation exempted certain 
facilities, identified in Annex 1 of the Proclamation, from compliance 
with the 2024 Final Rule. The Presidential exemption is for a period of 
2 years beyond the 2024 Final Rule's compliance dates. During the 
exemption period, facilities identified in Annex 1 that were subject to 
the Commercial Sterilization Facilities NESHAP, 40 CFR part 63, subpart 
O, in effect prior to the issuance of the 2024 Final Rule must continue 
to comply with those standards.
---------------------------------------------------------------------------

    \33\ A copy of the Presidential Proclamation and Annex 1 are 
available in the rulemaking docket (Docket ID No. EPA-HQ-OAR-2019-
0178).
---------------------------------------------------------------------------

III. Reconsideration and Other Issues, Proposed Changes and Rationale

    The EPA is proposing amendments to the Commercial Sterilization 
Facilities NESHAP. Specifically, the EPA is proposing to rescind 
standards promulgated under CAA section 112(f)(2), to revise the 
standard promulgated under CAA section 112(d)(6) for new ARVs at 
facilities using at least 10 tpy of EtO, to amend the compliance 
demonstration requirements to allow facilities to choose between 
parametric monitoring or CEMS, and to rescind the requirement that PTE 
be used to ensure complete capture of EtO. The EPA is also proposing 
technical corrections and clarifications to the Commercial 
Sterilization Facilities NESHAP and PS 19. The subsequent sections of 
this preamble describe these changes in detail as well as provide the 
EPA's reasoning for the proposed changes. Table 3 summarizes the 
proposed changes to emission limits that would result from this 
reconsideration. Specifically, the table shows the proposed rescission 
of CAA section 112(f)(2) standards and the resulting changes in 
applicable standards affected by this rescission. It also shows the 
proposed revised standard for new ARVs at facilities using at least 10 
tpy of EtO (i.e., 99.6 percent reduction).
BILLING CODE 6560-50-P
[GRAPHIC] [TIFF OMITTED] TP17MR26.014


[[Page 12710]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.015


[[Page 12711]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.016


[[Page 12712]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.017

BILLING CODE 6560-50-C

A. What changes are we proposing for the CAA section 112(f)(2) 
standards, and what is the rationale for those decisions?

    The EPA is proposing to rescind the risk-based standards 
promulgated in 2024 pursuant to CAA section 112(f)(2) for the reasons 
explained below.
    In 2006, the EPA finalized the RTR for the Commercial Sterilization 
Facilities source category pursuant to CAA sections 112(f)(2) and 
112(d)(6), consisting of both the eight-year residual risk review under 
section 112(f)(2) and the first technology review of the NESHAP for 
this source category pursuant to section 112(d)(6).\34\ The EPA 
determined that the MACT standards protected public health and welfare 
with an ample margin of safety and that any revisions would achieve 
minimal emissions reductions at high cost, such that no revisions were 
necessary under CAA section 112(f)(2) or CAA section 112(d)(6). For 
purposes of the risk review, the EPA relied on evidence and assessments 
available at that time, including a cancer risk evaluation developed by 
California EPA that was informed by a prior evaluation developed by the 
EPA. Since the 2006 RTR, the EPA was subject to a mandatory duty suit 
in connection with the ongoing obligation to review the standards under 
CAA section 112(d)(6) but did not seek to revisit the residual risk 
review until the rulemaking that resulted in the 2024 Final Rule.
---------------------------------------------------------------------------

    \34\ 71 FR 17712 (Apr. 7, 2006).
---------------------------------------------------------------------------

    In the 2024 Final Rule, the EPA for the first time implemented an 
interpretation of CAA section 112(f)(2) that allowed the Agency to 
conduct another residual risk review for this source category and 
promulgate additional risk-based standards. In doing so, we 
acknowledged that ``CAA section 112(f)(2) requires only a one-time risk 
review, which is to be conducted within eight years of the date the 
initial standards are promulgated.'' \35\ However, we also concluded 
that ``[CAA section 112(f)(2)] does not limit our discretion or 
authority to conduct another risk review should we consider that such 
review is warranted.'' \36\ The EPA has since revisited the explanation 
for this interpretation and proposes that it is incorrect for the 
following reasons.\37\
---------------------------------------------------------------------------

    \35\ 89 FR 24090 (Apr. 5, 2024).
    \36\ Id.
    \37\ See Summary of Public Comments and Responses for Risk and 
Technology Review for Ethylene Oxide Sterilization Facilities 
(February 2024) (2024 Rule RTC) (Document ID No. EPA-HQ-OAR-2019-
0178-1595), 229-33.
---------------------------------------------------------------------------

    First, in 2024, the EPA concluded that the CAA authorizes 
additional, discretionary risk reviews because the statute ``does not 
prohibit the EPA from revisiting standards promulgated under . . . CAA 
section 112(f)(2).'' \38\ However, the EPA did not consider at the time 
that a limitation on authority must sometimes be inferred from the 
structure of the provision and surrounding statutory language. 
``[W]here Congress includes particular language in one section of a 
statute but omits it in another section of the same Act, it is 
generally presumed that Congress acts intentionally and purposely in 
the disparate inclusion or exclusion.'' \39\ Here, Congress enacted a 
detailed process and timeline for developing and revising HAP emission 
standards under CAA section 112(d), including the general authority and 
obligation to promulgate regulations for each listed source category 
under section 112(d)(1), the development of MACT standards under 
section 112(d)(2)-(3), the health-threshold and area-source regulatory 
alternatives under section 112(d)(4) and (5), respectively, and the 
ongoing obligation to review and revise standards ``as necessary'' 
every eight years under section 112(d)(6). In contrast, CAA section 
112(f) sets out a one-time obligation and authority to conduct a risk 
review for each source category within eight years of promulgating MACT 
standards, including a requirement to promulgate additional standards 
if the MACT standards-setting process did not adequately address 
residual risk and provide an ample margin of safety. One can infer from 
the explicit requirement to conduct subsequent technology reviews in 
CAA section 112(d)(6), and the absence of such a requirement in section 
112(f)(2),

[[Page 12713]]

that Congress did not authorize multiple risk reviews under section 
112(f)(2).
---------------------------------------------------------------------------

    \38\ Id. at 229.
    \39\ Nken v. Holder, 556 U.S. 418, 430 (2009) (quoting INS v. 
Cardoza-Fonseca, 480 U.S. 421, 432 (1987)); see also Russello v. 
United States, 464 U.S. 16, 23 (1983).
---------------------------------------------------------------------------

    Second, the EPA's prior interpretation did not fully consider the 
overall statutory framework of CAA section 112. ``It is a fundamental 
canon of statutory construction that the words of a statute must be 
read in their context and with a view to their place in the overall 
statutory scheme.'' \40\ Here, Congress explicitly set forth a system 
of recurring technology reviews every eight years under CAA section 
112(d)(6) and a one-time risk review under section 112(f). In addition, 
Congress stated twice in section 112(f)(2) that any required standard 
must be promulgated within 8 years of promulgating section 112(d) 
standards.\41\ Reading section 112(f)(2) to allow more than one 
residual risk review that could result in additional risk standards 
long after the eight-year statutory deadline, in this case twenty years 
after section 112(d) standards were promulgated in 1994, ``would 
effectively gut Congress's carefully articulated existing system.'' 
\42\ Moreover, Congress enacted the detailed regulatory scheme in CAA 
section 112 with the express goal of achieving rapid regulation of the 
HAP identified in CAA section 112(b) across all relevant source 
categories.\43\ An implied authority to conduct discretionary risk 
reviews on an ad hoc basis disrupts the statutory scheme by eliminating 
the finality of residual risk reviews, undermining certainty for 
regulated industry and the public, and placing certain source 
categories on a different trajectory from the rest, all without 
providing a standard for the use of such implied discretion. This 
approach is also inconsistent with CAA section 112(f) itself, which 
envisions potential further action from Congress to address residual 
risk. CAA section 112(f)(1) required the Agency to develop a report on 
the calculation of residual risk, the impacts of such risk, including 
the costs of control, and recommendations for further legislation. CAA 
section 112(f)(2) required the one-time residual risk within eight 
years only if ``Congress does not act on any recommendation submitted 
under paragraph (1).'' In this way, CAA section 112 contemplates a one-
time residual risk review, followed by ongoing reductions achieved, 
when ``necessary,'' through the promulgation of additional standards 
under CAA section 112(d)(6).
---------------------------------------------------------------------------

    \40\ West Virginia v. EPA, 597 U.S. 697, 721 (2022) (internal 
quotations omitted).
    \41\ See CAA sections 112(f)(2)(A) and (C).
    \42\ Loving v. I.R.S., 742 F.3d 1013, 1020 (D.C. Cir. 2014) 
(finding IRS's regulations of tax preparers to be invalid because, 
among other factors, the overall statutory framework did not support 
IRS's interpretation of the statute to encompass authority to 
regulate those entities); see also Natural Resources Def. Council v. 
Regan, 67 F.4th 397, 404 (D.C. Cir. 2023) (``Regardless of how 
serious the purported problem an administrative agency seeks to 
address, it may not exercise its authority in a manner that is 
inconsistent with the administrative structure that Congress enacted 
into law.'' (citation modified)).
    \43\ Per CAA section 112(e), Congress required the Agency to 
promulgate MACT standards for all listed source categories by 2000, 
with intervening milestones in 1992, 1994, and 1997. Initial source 
categories and subcategories were to be listed by 1990 under CAA 
section 112(c). The RTRs for those source categories were to be 
completed within eight years of the initial standards, meaning that 
by approximately 2008, all source categories would be regulated 
under standards that provide an ample margin of safety. The 
periodic, eight-year technology review under CAA section 112(d)(6) 
is the only ongoing review-and-revise obligation for a provision 
consciously designed to achieve protections for the HAPs Congress 
listed for regulation in the 1990 CAA Amendments.
---------------------------------------------------------------------------

    Third, the EPA did not appropriately grapple with relevant 
regulatory history. The 2024 Final Rule, together with a handful of 
actions issued several months later, marked the first time that the 
Agency had completed a second, ``discretionary'' residual risk review 
and imposed corresponding standards under CAA section 112(f)(2). The 
novelty of this approach presents an additional reason to proceed with 
caution. In prior actions, including the Benzene NESHAP incorporated by 
reference into the statute in CAA section 112(f)(2)(B), the EPA had 
acknowledged that residual risk reviews entail significant uncertainty 
accounted for, in part, by providing an ample margin of safety, and had 
not taken the position that follow-on risk reviews under CAA section 
112(f)(2) were the appropriate mechanism to address new information. 
Rather, the EPA has reviewed and revised ``as necessary'' under CAA 
section 112(d)(6), including by evaluating the cost-effectiveness of 
potential developments by reference to the nature of the risk posed by 
the particular HAP at issue (i.e., by accepting higher values for cost-
per-ton of emission reduction for extremely dangerous HAP).\44\ We 
propose that contrary statements made in the 2024 Final Rule, including 
the statement that ``the EPA's discretion to revise prior standards 
where the statute does not contain limiting language . . . has been 
implemented without controversy,'' misapprehended the nature of the 
cited actions and did not account for the mine run of consistent 
regulatory practice.\45\ We further propose that the 2024 Final Rule 
overread the statement in the 2006 RTR that, in response to a comment 
suggesting residual risk reviews should account for future 
uncertainties, the Agency may ``revisit (and revise, if necessary) any 
rulemaking if there is sufficient evidence'' for doing so, citing to 
CAA section 301.\46\ Read in context, this statement is better 
understood as a general reference to the EPA's authority to reconsider 
and revise under CAA section 112(d)(6), which is where the operative 
term ``necessary'' appears in the statute. In any event, that statement 
does not stand for the proposition that the Agency anticipated 
finalizing an entirely new residual risk review and associated 
standards nearly 20 years later based on a new record and new 
considerations, nor did it grapple with the text and structure of the 
statute as we propose to do in this action.
---------------------------------------------------------------------------

    \44\ See National Emission Standards for Hazardous Air 
Pollutants: Coal- and Oil-Fired Electric Utility Steam Generating 
Units: Final Repeal, 91 FR 9088, 9099 (Feb. 24, 2026) (``2026 MATS 
Repeal'') (explaining that ``the statutory benchmarks for risk 
provide relevant guidance on whether additional regulation is 
`necessary' under CAA section 112(d)(6)'').
    \45\ 2024 Rule RTC at 229-33. For example, the EPA cited at that 
time a prior action to revise new locomotive and engine standards 
under CAA section 213(a)(5) without acknowledging the substantially 
different text and structure of that provision. Id. Similarly, the 
EPA cited prior actions to remove standards or revise a MACT floor 
that did not involve the imposition of new standards under CAA 
section 112(f)(2). Id.
    \46\ 71 FR 17715-16 (citing 42 U.S.C. 7601).
---------------------------------------------------------------------------

    Lastly, the EPA cited CAA section 307(d)(1)(C) as supporting the 
EPA's authority to conduct a discretionary risk review. The EPA 
concluded that this provision ``assumes the EPA might review standards 
set under 112(f)(2) and imposes CAA section 307(d) rulemaking processes 
on such revisions, when conducted.'' \47\ Section 307(d)(1)(C), which 
references ``the promulgation or revision of . . . any standard under 
section [112(f)(2)],'' acknowledges that there are situations where 
section 112(f)(2) standards might be revised, not that the EPA has the 
discretion to revise such standards when it chooses. For example, the 
EPA might have to revise a section 112(f)(2) standard as the result of 
an adverse judicial decision or mandatory administrative 
reconsideration under CAA section 307(d)(7)(B). Under those scenarios, 
the EPA would be required to reconsider a prior risk review. However, 
because the EPA may be required to reconsider and revise section 
112(f)(2) standards in certain limited circumstances does not speak to 
whether the EPA may conduct a discretionary second risk review.
---------------------------------------------------------------------------

    \47\ See id.
---------------------------------------------------------------------------

    For these reasons, the EPA proposes to find that the CAA does not 
authorize the discretionary second risk review that the Agency 
conducted for this source category in 2024. The EPA is therefore 
proposing to rescind the risk

[[Page 12714]]

standards promulgated in the 2024 rule. These standards can be seen in 
---------------------------------------------------------------------------
table 3 and are as follows:

 99.99 percent reduction for new and existing SCVs where EtO 
use is at least 30 tpy
 99.9 percent reduction for new and existing SCVs where EtO use 
is at least 10 but less than 30 tpy
 99.9 percent reduction for new and existing ARVs where EtO use 
is at least 30 tpy
 99.6 percent reduction for existing ARVs where EtO use is at 
least 10 but less than 30 tpy
 99.9 percent reduction for area source CEVs where EtO use is 
at least 60 tpy
 98 percent reduction for new and existing Group 1 room air 
emissions where EtO use is at least 40 tpy
 98 percent reduction for new and existing Group 2 room air 
emissions where EtO use is at least 20 tpy
 80 percent reduction for new and existing Group 2 room air 
emissions where EtO use is at least 4 but less than 20 tpy

    After the proposed removal of these risk-based standards, affected 
sources would be required to comply with their section 112(d)(2) and 
(3) or 112(d)(5) standards; if such standards have been revised 
pursuant to section 112(d)(6), affected sources would comply with their 
section 112(d)(6) standards. Additionally, the EPA proposes that for 
existing source Group 2 room air emissions, facilities may choose to 
comply with either the existing source standard (lower EtO 
concentration to 1 ppm before opening the aeration chamber) or the new 
source standard (80 percent reduction of EtO). The EPA is proposing 
this change to address concerns that the existing source standard may 
impact the supply chain of medical equipment. Table 3 above identifies 
the applicable standards for these affected sources with the removal of 
the section 112(f)(2) standards.
    The proposed amendments would remove the EtO-usage based 
subcategories that resulted from the section 112(f)(2) standards, and 
facilities that would have been subject to those standards would 
instead be subject to the appropriate subcategories as promulgated by 
the 2024 Final Rule under section 112(d)(2), (3), (5), or (6). For 
instance, for both new and existing SCVs, EtO use categories for 
facilities where EtO use is at least 30 tpy, and for facilities where 
EtO use is at least 10 tpy but less than 30 tpy under CAA section 
112(f)(2), would also be removed in conjunction with the proposed 
rescission of section 112(f)(2) standards. As a result, these 
facilities will all be in the subcategory of facilities where EtO use 
is at least 10 tpy. Similarly, for new and existing ARVs, with the 
removal of subcategories established under section 112(f)(2) for 
facilities where EtO use is at least 30 tpy and facilities where EtO 
use is at least 10 tpy but less than 30 tpy, these facilities would all 
comprise a single subcategory of facilities where EtO use is at least 
10 tpy.
    Additionally, area sources of CEVs, Group 1 room air emissions, 
existing Group 2 room air emissions, and new Group 2 room air emissions 
would each have a single standard rather than different risk-based 
standards due to subcategorization based on a facility's EtO use under 
section 112(f)(2). The EPA is proposing amendments to the applicable 
standards in tables 1 to 5 to subpart O of part 63 to address these 
changes. The EPA is soliciting comment on the proposed removal of the 
CAA section 112(f)(2) emission standards and all related questions of 
statutory interpretation, including any additional regulatory history 
or case law bearing on the best reading of CAA section 112 and the 
Agency's rationale for changing the position taken in the 2024 Final 
Rule and related actions (Question 2).
    Separate from the EPA's position on the Agency's authority to 
conduct a second CAA section 112(f)(2) risk review described above, we 
are proposing that significant uncertainties regarding the magnitude of 
EtO's carcinogenic potency, particularly at low concentrations, would 
be an additional reason for rescinding the EtO standards in the 2024 
Rule and seeking detailed comment on this issue from interested 
stakeholders. Specifically, we propose that it would not be appropriate 
to rely on the 2016 EtO IRIS value in setting standards. If this 
position is finalized, the EPA would evaluate as necessary and 
appropriate in future regulatory actions other EtO risk values, ranges, 
or additional means to assess risk when relevant to the statutory 
scheme.
    Because such comment submissions will be essential to informing 
whether this proposed rationale is an appropriate basis for taking 
final action, we request that interested stakeholders provide relevant 
data, studies, and analyses to support any claims made about the 
adequacy or inadequacy of the 2016 EtO IRIS value and any alternative 
values the commenter believes would be more appropriate and consistent 
with the statutory framework. If commenters believe a range or multiple 
potential values would be appropriate or wish to opine on the breadth 
of the Agency's discretion to select among values, we ask that the 
commenter support such assertions with appropriate citations. Although 
the EPA will respond to all significant comments received, we view such 
information as critical to ensuring that the record reflects all 
perspectives and relevant information given the highly technical nature 
of issue and the breadth of potentially relevant scientific and other 
literature.
    The EPA previously acknowledged that uncertainties regarding the 
magnitude of EtO's carcinogenic potency could materially affect risk 
estimates, thereby substantially informing the risk evaluation as a 
whole and any resulting standards. As discussed in a 2019 technical 
memorandum,\48\ the EPA identified two key sources of uncertainty in 
the 2016 EtO IRIS value: dose-response model selection and the use of 
the statistical upper confidence limit. Regarding the former, during 
the development of the 2016 EtO IRIS value, the EPA considered many 
different dose-response models to describe the available lymphoid 
cancer data. Several of these models, including the one the EPA 
ultimately selected, fit the exposure data well. However, the EPA 
estimated that choosing one of the alternative viable models could have 
resulted in an EtO IRIS value up to two times lower than the final 2016 
EtO IRIS value. Regarding the latter, while the EPA chose to focus on 
the statistical upper confidence limit of the cancer value, the Agency 
later estimated that using the statistical central estimate instead 
could have resulted in an EtO IRIS value up to three times lower than 
the final value. The technical memo concluded that, if combined, these 
two factors could have resulted in an EtO IRIS value that was up to 
five times lower (i.e., EtO is five times safer than the 2016 EtO IRIS 
value provided). The analysis in the technical memorandum demonstrates 
that both model selection and the underlying cancer data (in this case 
epidemiological studies of cancer in humans exposed to EtO) can greatly 
influence the resulting risk estimate. It is important to note that the 
analysis in the technical memorandum relies entirely on results and 
equations presented in the final EtO IRIS assessment, which was peer 
reviewed by EPA's Science Advisory Board.
---------------------------------------------------------------------------

    \48\ Sensitivity of Ethylene Oxide Risk Estimates to Dose-
Response Model Selection. Memorandum drafted by EPA's Office of 
Research and Development, docketed in the Miscellaneous Organic 
Chemical Manufacturing NESHAP Proposed Rule, 84 FR 69182 (Dec. 17, 
2019).
---------------------------------------------------------------------------

    The EPA recognizes that the Agency defended its use of the 2016 EtO 
IRIS value in Huntsman Petrochemical LLC

[[Page 12715]]

v. EPA.\49\ In that case, industry groups challenged the EPA's 2020 
Miscellaneous Organic Chemical Manufacturing NESHAP (MON) rule \50\ and 
the EPA's 2022 reconsideration of that rule.\51\ The main issues raised 
in industry's reconsideration petition and the resulting consolidated 
litigation were whether the EPA acted reasonably in using the 2016 EtO 
IRIS value and rejecting the Texas Commission on Environmental 
Quality's (TCEQ) alternative value. Industry challenged numerous 
technical decisions made by the EPA in the course of developing the 
2016 EtO IRIS value, including but not limited to, model selection and 
choice of underlying epidemiological studies and exposure 
estimates.\52\ Ultimately, the U.S. Court of Appeals for the D.C. 
Circuit denied the petitions for review of the 2020 MON Rule and the 
2022 reconsideration, finding that Petitioners failed to show that EPA 
had acted arbitrarily and capriciously in using the 2016 EtO IRIS 
value.\53\
---------------------------------------------------------------------------

    \49\ 114 F.4th 727 (D.C. Cir. 2024).
    \50\ 85 FR 49,084 (Aug. 12, 2020).
    \51\ 87 FR 77,985 (Dec. 21, 2022).
    \52\ See Huntsman, 114 F.4th at 737-40.
    \53\ Id. at 742.
---------------------------------------------------------------------------

    While the EPA defended its use of the 2016 EtO IRIS value in the 
2020 MON rule and subsequent reconsideration action, the Agency 
acknowledged at the time it issued the rule that significant 
uncertainties remained regarding the magnitude of EtO's carcinogenic 
potency, as discussed above. It is known that EtO can be produced 
within the body (endogenously) via normal metabolic processes and that 
tobacco smoke is a source of EtO exposure. However, the EPA recognized 
that uncertainties remained regarding the quantity and relative 
contribution of endogenous, tobacco smoke, and background EtO levels 
from non-industrial sources. Furthermore, the EPA recognizes that new 
empirical data may trigger a need to reevaluate toxicity values. For 
example, prior to 2016, the EPA used a toxicity value derived in 1985 
to estimate the cancer risk from EtO and, in rulemakings including the 
2006 RTR for the Commercial Sterilization Facilities NESHAP, used 
assessments that were informed by and built upon that value (including 
an analysis issued by the California EPA). Such values reflected the 
best evidence available at that time, but newer epidemiological studies 
later prompted both the EPA and TCEQ to produce updated 
assessments.\54\ Since the EPA defended the use of the 2016 EtO IRIS 
value in Huntsman, new scientific evidence has continued to 
emerge.55 56 While it is not entirely clear how many new 
studies or methodological advancements have developed in recent years, 
given the sensitivity of EtO risk estimates at low concentrations to 
both model selection and the underlying cancer data, it is plausible 
that any new information could change the EPA's understanding of EtO's 
carcinogenic potency. Therefore, the EPA is proposing that the 
significant uncertainties in the 2016 EtO IRIS value are an additional 
reason to support reconsideration and repeal of the 2024 Final Rule, 
separate and apart from the limits on our authority to conduct a 
residual risk review under CAA section 112(f)(2), and seeking detailed 
comment on that issue as indicated throughout this section.
---------------------------------------------------------------------------

    \54\ Both the 2016 EtO IRIS and the 2020 EtO TCEQ assessments 
have undergone expert peer review by authoritative bodies. See 
Science Advisory Board (SAB). 2015. Science Advisory Board Review of 
the EPA's Evaluation of the Inhalation Carcinogenicity of Ethylene 
Oxide (Revised External Review Draft--August 2014). EPA-SAB-15-012.; 
and National Academies of Sciences, Engineering, and Medicine. 2025. 
Review of Texas Commission on Environmental Quality's Ethylene Oxide 
Development Support Document. Washington, DC: The National Academies 
Press.
    \55\ Kelly-Reif K., Bertke S.J., Stayner L., Steenland K. 
Exposure to Ethylene Oxide and Relative Rates of Female Breast 
Cancer Mortality: 62 Years of Follow-Up in a Large US Occupational 
Cohort. Environ Health Perspect. 2025 May;133(5):57013. doi: 
10.1289/EHP15566. Epub 2025 May 22. PMID: 40168621; PMCID: 
PMC12097532.
    \56\ Valdez-Flores C, Li A.A., Bender T.J., Teta M.J. Use of 
updated mortality study of ethylene oxide manufacturing workers to 
inform cancer risk assessment. Risk Anal. 2025 Sep;45(9):2822-2837. 
doi: 10.1111/risa.70057. Epub 2025 Jun 3. PMID: 40458005; PMCID: 
PMC12474530.
---------------------------------------------------------------------------

    Specifically, the EPA is soliciting comment on any new information 
related to the underlying cancer data, such as epidemiological studies 
of cancer in humans exposed to EtO or advancements relevant to 
analyzing the relationship between occupational human exposure to EtO 
and the development of cancer not yet considered by the Agency 
(Question 3). Given the acknowledged impact of model selection, the EPA 
is also soliciting comment on any new or updated information relevant 
to dose-response model selection such as consideration of statistical 
analyses, visual model fit, or biological plausibility (Question 4). 
Further, the EPA is soliciting comment on any new or updated studies on 
human exposure to EtO, including information on occupational, smoking, 
background, or endogenous exposures not yet considered by the Agency 
(Question 5). The EPA anticipates that such information would be useful 
for updating the Agency's understanding of EtO exposure and toxicity 
and determining whether the 2016 EtO IRIS value remains suitable for 
estimating risk to inform regulatory decision-making. Finally, 
acknowledging that the EPA has received additional comments on the 2016 
EtO IRIS value in the context of other rulemaking proposals issued 
after the 2024 Commercial Sterilizers final rule, the EPA is soliciting 
comment on the information provided in those comments; this includes 
information provided by commenters in the context of the more recent 
proposed Chemical Manufacturing Area Sources NESHAP (January 22, 2025) 
(see Docket ID EPA-HQ-OAR-2024-0303, comment numbers 0060, 0061, 0068, 
0076, and 0079) (Question 6). As noted previously, we ask that 
commenters support claims with respect to the 2016 EtO IRIS value, any 
alternative value, or any alternative range or approach to determining 
risk with relevant data, studies, analyses, and other citations that 
the commenter believes should be considered in tandem with, or instead 
of, the previously recognized uncertainties in the IRIS methodology.

B. What changes are we proposing for the CAA section 112(d)(6) 
standards, and what is the rationale for those decisions?

    The 2024 Final Rule also included a technology review pursuant to 
CAA section 112(d)(6) for the Commercial Sterilization Facilities 
source category that resulted in revisions to certain standards. Among 
these revisions were emission standards for both new and existing ARVs 
at facilities where EtO use is at least 10 tpy. The standard for new 
ARVs at facilities using at least 10 tpy of EtO was 99.9 percent 
reduction, and the standard for existing ARVs at facilities using at 
least 10 tpy of EtO was 99.6 percent reduction. The EPA established the 
new source standard based on the conclusion that it achieved greater 
reduction and was more cost-effective than the two options considered 
(the other option being 99.6 percent reduction). The EPA set the 
existing source standard at a level that the Agency determined to be 
achievable by all sources.\57\
---------------------------------------------------------------------------

    \57\ 89 FR 24090 (Apr. 5, 2024).
---------------------------------------------------------------------------

    The EPA continues to believe that the standard for existing ARVs at 
facilities using at least 10 tpy of EtO is reasonable. The data 
provided by industry when developing the 2024 Final Rule demonstrates 
that 75 percent of facilities already achieve 99.6 percent reduction, 
and 50 percent already achieve 99.9 percent reduction of EtO from ARVs, 
demonstrating for purposes

[[Page 12716]]

of relevant considerations under CAA section 112(d)(6) that the 
enhanced standard is reasonable and properly considered ``necessary'' 
as a revision.\58\ However, for the reasons explained below, the EPA is 
proposing to amend the standard for new ARVs at facilities using at 
least 10 tpy of EtO to 99.6 percent reduction.
---------------------------------------------------------------------------

    \58\ Although rates of achievement by individual sources are 
often an indicator that revisions to a standard are ``necessary,'' 
that is not always the case, particularly when the costs of controls 
are very high and the remaining risks are very low. See, e.g., 2026 
MATS Repeal, 91 FR 9088 (Feb. 7, 2026).
---------------------------------------------------------------------------

    During the development of the 2024 Final Rule, for new ARVs at 
facilities where EtO use is at least 10 tpy, the EPA evaluated the 
cost-effectiveness of two options: 99.6 percent EtO reduction and 99.9 
percent reduction.\59\ When preparing cost-effectiveness calculations 
for new sources, the EPA based the calculations on a model plant for 
new ARVs reflecting the average number of ARVs, EtO use, and operating 
hours as an existing facility.\60\ This resulted in the following cost-
effectiveness values for the two options: $2.2 million per ton at a 
99.9 percent EtO reduction and $2.6 million at a 99.6 percent EtO 
reduction. As a result, the EPA promulgated the 99.9 percent EtO 
reduction standard for new ARVs at facilities where EtO use is at least 
10 tpy because it would achieve greater emission reductions and be more 
cost-effective than a 99.6 percent reduction standard.\61\ However, 
upon reconsideration, the EPA realizes that our cost-estimate approach 
did not accurately reflect the costs of new ARVs installed at existing 
facilities. Specifically, the EPA did not consider that, under the 99.6 
percent reduction option, which would result in the same standards for 
both new and existing ARVs, a new ARV could share and make use of 
ductwork, control devices, and other existing infrastructure for the 
ARVs already in place at the facility; therefore, the expected capital 
and annual costs for the 99.6 percent reduction option would be much 
lower than the estimate in the 2024 Final Rule. Sharing controls would 
also reduce the amount of auxiliary fuel burned in combustion-type 
control devices. Further, it is common practice for facilities to share 
ductwork or control devices across multiple sources, and the 99.6 
percent reduction option, which would result in a single standard for 
both new and existing ARVs at facilities using at least 10 tpy of EtO, 
has the benefit of allowing facilities to share infrastructure, 
streamline facility operations, and reduce costs.
---------------------------------------------------------------------------

    \59\ For a detailed discussion of cost-effectiveness, see 
section III.F.3 of the 2023 proposal preamble, 88 FR 22790 (Apr. 13, 
2023).
    \60\ 88 FR 22790 (Apr. 13, 2023).
    \61\ 88 FR 22841 (Apr. 13, 2023).
---------------------------------------------------------------------------

    For the reasons explained above, the EPA is proposing to change 
from 99.9 to 99.6 percent reduction for new ARVs at facilities with EtO 
use of at least 10 tpy, resulting in a single uniform standard for both 
new and existing ARVs at these facilities. This standard reflects the 
level already achieved by 75 percent of ARVs for which the EPA has 
data. The EPA is soliciting comment on this proposed emission standard, 
the approach by which the EPA arrived at this decision, and data 
regarding the costs of installing ARVs at existing facilities versus 
new facilities (Question 7).
    Additionally, some industry representatives have suggested that the 
ARV standards be based on manufacturer guaranteed levels for emission 
reductions. This issue was also raised during the rulemaking that led 
up to the 2024 Final Rule.\62\ At that time, industry concerns 
regarding this topic were focused on the requirement to use CEMS for 
demonstrating compliance. However, as discussed in the following 
section of this document, the EPA is proposing to revise the standards 
so that the use of CEMS is no longer mandatory. In any case, while the 
EPA is significantly concerned about setting standards more stringent 
than manufacturer certifications, the Agency does not have data on the 
manufacturer's guaranteed levels for reducing ARV emissions. As such, 
the EPA is also soliciting comment on whether there is still a concern 
that would necessitate considering setting ARV standards based on 
manufacturer guaranteed levels and, if so, what the manufacturer 
guaranteed level of EtO reduction is for ARVs (Question 8).
---------------------------------------------------------------------------

    \62\ 88 FR 24090 (Apr. 5, 2024).
---------------------------------------------------------------------------

C. What changes are we proposing for initial and continual compliance 
with the emission reduction standards, and what is the rationale for 
those decisions?

    The 2024 Final Rule requires compliance demonstration using EtO 
CEMS for all facilities except those using less than 100 lb/year 
``because risk remains at acceptable levels for these facilities even 
when considering uncontrolled emissions.'' \63\ The 2024 Final Rule 
allows these facilities with ``acceptable [risk] levels'' the option of 
using either parametric monitoring and performance testing or CEMS to 
demonstrate compliance with the promulgated emission standards. The EPA 
acknowledged that ``in the majority of instances, parametric monitoring 
is used to good effect as an ongoing means of ensuring that the control 
devices continue to get necessary emission reductions.'' \64\ The EPA 
is proposing to provide all facilities, including those using at least 
100 lb/yr of EtO, the option of using either parametric monitoring and 
performance testing or CEMS to demonstrate compliance for the following 
reason.
---------------------------------------------------------------------------

    \63\ 89 FR 24132 (Apr. 5, 2024).
    \64\ Id.
---------------------------------------------------------------------------

    Under the 2024 Final Rule, whether EtO CEMS is required is based on 
facility risks, which were derived from a second residual risk 
assessment the EPA conducted for this source category under CAA section 
112(f)(2). However, for the reasons explained in section III.A of this 
preamble, the EPA is proposing that CAA section 112(f)(2) does not 
authorize the EPA to conduct a second residual risk review and 
promulgate associated risk-based standards when the RTR has already 
been completed and the ongoing review-and-revise obligation and 
authority arises only under CAA section 112(d)(6). Because the EtO CEMS 
requirement was based on the results of an unauthorized second residual 
risk assessment and risk-based standards-setting for this source 
category, the EPA is proposing to amend the 2024 Final Rule to remove 
EtO CEMS as a requirement for facilities using at least 100 lb/yr of 
EtO and instead allow all facilities, regardless of the amount of EtO 
used, the option to choose between parametric monitoring or CEMS for 
demonstrating compliance. As proposed, both demonstration options would 
be available for all facilities. The EPA thus proposes revisions to 40 
CFR 63.363(a), (b), (d), (e), and (f)(2) and to 63.365(a), (b), (c), 
and (d) to allow initial and continuous compliance with annual 
performance testing and parameter monitoring, and to allow EtO CEMS as 
an alternative compliance option. The EPA is soliciting comment on 
allowing all facilities the option to choose between parametric 
monitoring or CEMS for demonstrating compliance (Question 9).
    In addition, the EPA is proposing amendments to the parametric 
monitoring provisions in the 2024 Final Rule. In reconsidering the 
compliance demonstration requirements in the 2024 Final Rule, the EPA 
noticed that the parametric monitoring provisions, which were 
promulgated in the original Commercial Sterilization Facilities NESHAP 
in 1994, with technical corrections in the 2001 amendments, do not 
reflect the current understanding of air pollution control devices 
(APCDs) or the sterilization process(es). The EPA is

[[Page 12717]]

thus proposing to update the monitoring parameters for APCDs in 40 CFR 
63.361, 63.363(c), and 63.364(b), (c), and (d). In addition, the EPA is 
proposing revisions to the procedures for establishing operating 
parameter limits during the performance test in 40 CFR 63.365(e). The 
EPA is also proposing clarifying language that describes where the 
performance testing should be conducted in 40 CFR 63.365(b)(1), 
providing for the myriad of APCD configurations expected from this 
source category. The proposed amendments for parametric monitoring are 
described in the following paragraphs.
    For those facilities that use acid-water scrubbers, thermal 
oxidizers, catalytic oxidizers, gas-solid reactors, or other control 
devices, the EPA is proposing they demonstrate compliance with the 
emission reduction standard through initial and annual performance 
testing and establish parametric operating limits. The EPA is also 
proposing to allow continuous compliance through parametric monitoring 
using a continuous parametric monitoring system. The EPA is proposing 
that facilities must determine compliance with the operating limits 
continuously on a 1-hour block basis instead of the current 3-hour 
block. Sterilization is an irregular process where the EtO emissions 
may fluctuate greatly with different steps in the process, some of 
which are less than three hours. Longer averaging times could mask how 
the emission controls operate and achieve the required control 
efficiency during operational periods immediately before or after 
higher EtO loading to the control devices (e.g., during SCV exhaust 
cycles).
    For facilities that use an acid-water scrubber, the current 
monitoring parameters are ethylene glycol concentration, scrubber 
liquid tank level, and scrubber liquid pH. Based on EPA's current 
understanding of acid-water scrubbers, the EPA believes that scrubber 
liquid-to-gas ratio and scrubber liquid temperature are more accurate 
indicators of compliance than ethylene glycol concentration and 
scrubber liquor tank level. The EPA believes this because they are 
direct indicators that EtO will be captured in the scrubbing columns 
and the parameters can be monitored in real-time to ensure continuous 
operation. The EPA is therefore proposing to require continuous 
monitoring of scrubber liquid-to-gas ratio, scrubber liquid 
temperature, and scrubber liquid pH. The Agency is proposing that 
during each annual performance test, the owner or operator determines 
the average scrubber liquid-to-gas ratio, average inlet scrubber 
temperature, and average scrubber liquid pH. The EPA is proposing these 
parameter test averages would be the operating limit for the minimum 
scrubber liquid-to-gas ratio, maximum temperature of the scrubber 
liquid, and the maximum scrubber liquid pH.
    For facilities that use thermal oxidizers, the current monitoring 
parameter in the rule is the temperature in or immediately downstream 
of the firebox. The EPA is proposing to require continuous monitoring 
of the combustion chamber temperature and flue gas flow rate. First, 
the Agency is proposing to replace the term ``firebox'' with 
``combustion chamber'' as the latter is a more commonly used term in 
the industry. Second, the EPA is proposing monitoring the combustion 
chamber temperature (instead of allowing the option of monitoring 
immediately downstream) at a location designated by pollution control 
manufacturers to ensure proper control and operation. Third, the Agency 
is also proposing to monitor flue gas flow rate. The flue gas flow rate 
provides an indication of the thermal oxidizer residence time, which is 
a critical operating parameter because it will ensure proper flow rate 
through the thermal oxidizer is being maintained to ensure the 
continued removal efficiency of any EtO in the sample stream sent to 
the oxidizer. The EPA is proposing that during each annual performance 
test facilities determine the average combustion chamber temperature 
and average flue gas flow rate. The EPA is proposing these parameter 
test averages would be the operating limit for the minimum combustion 
temperature and maximum flue gas flow rate.
    For facilities that use a catalytic oxidizer, the current 
parameters are the temperature at the inlet to the catalyst bed and the 
temperature difference across the catalyst bed, which requires 
monitoring the inlet temperature to the catalyst bed and the outlet 
temperature to the catalyst bed. The EPA is proposing to also require 
continuous monitoring of flue gas flow rate. The flue gas flow rate 
parameter would provide an indication of the catalytic oxidizer 
residence time, which is a critical operating parameter because it will 
ensure that proper flow rate through the catalytic oxidizer is being 
maintained to ensure the continued removal efficiency of any EtO in the 
sample stream sent to the oxidizer. Thus, the Agency is proposing to 
require continuous monitoring of the inlet and outlet temperatures and 
flue gas flow rate. The EPA is proposing that during each annual 
performance test, facilities determine the average inlet temperature to 
the catalyst bed, the average temperature difference between the inlet 
and the outlet of the catalyst bed, and average flue gas flow rate. The 
EPA is proposing these parameter test averages would be the operating 
limit for the minimum temperature at the inlet to the catalyst bed, the 
minimum temperature difference across the catalyst bed, and the maximum 
flue gas flow rate.
    For facilities that use a gas-solid reactor, the current parameters 
include bed media analysis (i.e., sample the bed media and analyze for 
activity) and the pressure drop across the media beds. In its place, 
the EPA is proposing that facilities must determine the average 
pressure drop across the reactor during each annual performance test 
and for this test average to be the operating limit for the maximum 
gas-solid reactor pressure drop. The EPA is also proposing that when a 
gas-solid reactor is used as the last air pollution control device 
prior to exhausting to the atmosphere, facilities must determine the 
EtO average mass emission sent to the pollution control and the outlet 
flow rate during the annual performance test. Using this information 
and the applicable emission reduction standard, facilities must 
calculate the upper gas-solid reactor outlet EtO concentration 
operating limit. The EPA is also proposing that compliance with the 
outlet EtO concentration operating limit must be measured and recorded 
weekly. Compared to the current media analysis, this proposed parameter 
monitoring provides a direct assessment of ongoing performance and will 
ensure that the control device is optimized, and that the applicable 
emission reduction standard is being met by meeting the set operating 
limit.
    To maximize flexibility in conducting parametric monitoring, the 
2024 Final Rule allows facilities to apply to the EPA Administrator for 
approval of alternative monitoring requirements for the typical APCDs. 
The EPA is proposing to provide the requirements to be included in the 
application for alternative monitoring parameters in 40 CFR 
63.365(e)(6).
    For those facilities using performance testing and a control device 
other than acid-water scrubbers, catalytic or thermal oxidizers, or 
gas-solid reactors, the 2024 Final Rule requires that facilities must 
establish operating limits and appropriate monitoring parameters that 
are approved by the EPA Administrator for that specific control device. 
In this action, the EPA is proposing that facilities must develop a

[[Page 12718]]

monitoring plan for their chosen continued compliance option 
(parametric monitoring or CEMS); see proposed rule text in 40 CFR 
63.364(a)(6) and (7).
    The EPA is proposing to update the reporting and recordkeeping 
requirements of the Commercial Sterilization Facilities NESHAP in 40 
CFR 63.366 and 63.367 to reflect the revised parametric monitoring 
discussed above. As required by the 2024 Final Rule, if there are 
deviations from the established operating parameter limits, facilities 
must report the deviation in the quarterly compliance report. 
Facilities must take corrective actions to minimize emissions and 
return the unit to normal operations. If the established operating 
parameters cannot be met after the corrective action, the facility must 
reset the operating parameters with a performance test.
    The EPA is soliciting comment on these proposed changes to the 
performance testing, parametric monitoring, and reporting requirements 
(Question 10).

D. What changes are we proposing to PTE requirements, and what is the 
rationale for those actions?

    The EPA is proposing to rescind the requirement to use PTE to 
ensure capture of EtO to comply with the emission reduction standards. 
In the 2024 Final Rule, the EPA finalized requirements to operate PTE 
in accordance with the requirements of Method 204 as a compliance 
assurance measure. In the proposal to the 2024 Final Rule, the EPA 
noted that these requirements were ``consistent with what has been 
applied to many of the commercial sterilizers that have installed PTEs, 
through permit conditions.'' \65\ In this reconsideration, we are 
reevaluating this approach. Based on our review of state permits for 
sterilization facilities, we note that some permits require PTE while 
others do not. We further note that configuration and design of 
sterilization facilities vary widely. The above observations suggest 
that whether PTE would be necessary to assure compliance with an 
emission standard could depend on a facility's design and 
configuration. The EPA has historically left such case-by-case reviews 
of facility design to the states to decide as part of their permitting 
process.
---------------------------------------------------------------------------

    \65\ See 88 FR 22819 (Apr. 13, 2023).
---------------------------------------------------------------------------

    The EPA is proposing in the alternative to rescind the requirement 
for PTE on the following bases. First, we propose that the EPA did not 
account for the impacts of facilities shutting down due to this 
variation. If the facility is unable to establish a PTE and meet the 
other requirements, then the facility would be required to shut down 
thus significantly raising the costs and making it not cost-effective 
to establish PTE. The feasibility of PTE has been raised by 
stakeholders over time with respect to this NESHAP, and we seek comment 
on this potential alternative basis (Question 11).
    Second, the EPA is proposing in the alternative that the PTE 
requirement is not compelled by the D.C. Circuit's decision in 
Louisiana Environmental Action Network v. Environmental Protection 
Agency (LEAN),\66\ meaning that, at minimum, the Agency has discretion 
whether to remove the PTE requirement as a compliance mechanism. In 
previous rules, the EPA has stated or suggested that LEAN requires the 
Agency, as part of the technology review process under CAA section 
112(d)(6), not only to regulate previously unregulated pollutants, but 
also to prescribe additional standards for already regulated pollutants 
emitted in a manner (i.e., from points or fugitive) not expressly 
contemplated under the existing standards. In LEAN, the D.C. Circuit 
discussed its view of the Agency's obligation to regulate previously 
unregulated (i.e., unaddressed) pollutants when conducting a technology 
review and revising standards ``as necessary'' under CAA section 
112(d)(6). In context, the court analyzed the statute with respect to, 
and referred specifically to, different types of air toxics (i.e., 
previously regulated and previously unregulated pollutants).\67\ In 
certain actions since that decision, however, the EPA has sometimes 
suggested that this holding includes not only previously unregulated 
pollutants, but also additional emission points within an already 
regulated source (e.g., an additional point or fugitive) that emit 
pollutants already captured by the NESHAP. We now propose to clarify 
that when conducting a CAA section 112(d)(6) review, the EPA is not 
obligated under the interpretation adopted in LEAN to prescribe 
particular standards for emission points with respect to pollutants 
already regulated under the NESHAP. If finalized, this proposed 
position would mean that the EPA's rationale for adopting the PTE 
requirement--i.e., that such a requirement was necessary to assure 
compliance with additional standards mandated by LEAN--is no longer 
operative, and we would decline to adopt such a requirement as a 
discretionary matter for the reasons discussed previously. The EPA 
requests comments on all aspects of these alternative proposals, 
including with respect to the scope of the interpretation adopted by 
the D.C. Circuit in LEAN and the scope of the Agency's obligation and 
statutory authority to impose additional standards under the CAA 
section 112(d)(6) process for particular emission points not previously 
regulated (Question 12).
---------------------------------------------------------------------------

    \66\ 955 F.3d 1088 (D.C. Cir. 2020)
    \67\ See id. at 1096.
---------------------------------------------------------------------------

    In light of the above, we propose to rescind the requirement to use 
PTE as a compliance assurance measure. The proposed change would not 
affect the permitting process for any state, which could continue to 
decide on a case-by-case basis, deferring to States to make the 
determination as States are in better positioned to determine whether 
PTE is required for any given sterilization facility. We solicit 
comment on this approach (Question 13).

E. What technical corrections and amendments to the Commercial 
Sterilization Facilities NESHAP are we proposing, and what is the 
rationale for those actions?

    After the publication of the 2024 Final Rule, the EPA discovered, 
through internal reassessment of the regulatory text and through 
communications with stakeholders, erroneous cross-references and 
typographical errors within the regulatory text. Through those same 
processes, the EPA also identified erroneous language in the regulatory 
text (or in some cases, erroneous omissions) requiring minor wording 
changes to conform with the 2024 Final Rule preamble and other parts of 
the regulatory text. The technical corrections and amendments 
identified here in subsection III.E.1 of this preamble are separate 
from the proposed substantive changes that resulted from 
reconsideration; the proposed technical changes and amendments address 
unintended errors in the 2024 Final Rule. The EPA is proposing these 
corrections and clarifications to the regulatory text so that the 
regulated community can rely on regulatory text that is accurate and 
complete and avoid confusion about how to comply with the Commercial 
Sterilization Facilities NESHAP. This action addresses the technical 
errors in the 2024 Final Rule identified to date by stakeholders and 
the EPA.

[[Page 12719]]

1. Technical Corrections to the Commercial Sterilization Facilities 
NESHAP
a. Cross-Reference and Typographical Errors
    Following promulgation of the 2024 Final Rule, both the EPA and 
stakeholders identified inadvertent errors in the regulatory text of 
the Commercial Sterilization Facilities NESHAP, including cross-
reference and typographical errors. Table 4 includes the section and 
paragraph of each identified error, the corrections being proposed in 
this action, and the reasoning for the corrections. The EPA is not 
soliciting comment on these corrections.
BILLING CODE 6560-50-P
[GRAPHIC] [TIFF OMITTED] TP17MR26.018


[[Page 12720]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.019


[[Page 12721]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.020


[[Page 12722]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.021


[[Page 12723]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.022

BILLING CODE 6560-50-C
b. Clarifying Technical Corrections
    This action proposes technical corrections to clarify language in 
the regulatory text of the Commercial Sterilization Facilities NESHAP 
that was erroneously included (or in some cases, erroneously omitted) 
in the 2024 Final Rule. Table 5 includes the sections and paragraphs of 
the identified errors, the corrections being proposed, and the 
reasoning for the corrections.

[[Page 12724]]

[GRAPHIC] [TIFF OMITTED] TP17MR26.023


[[Page 12725]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.024

BILLING CODE 6560-50-C

[[Page 12726]]

    A redline strike-out version of the proposed corrected regulatory 
language for the Commercial Sterilization Facilities NESHAP is 
available in Docket ID No. EPA-HQ-OAR-2019-0178.
2. Proposed Amendments to the Commercial Sterilization Facilities 
NESHAP
    In addition to the technical corrections discussed above, the EPA 
is proposing additional amendments to the Commercial Sterilization 
Facilities NESHAP that are more substantive in nature.
a. Definition of Operating Day
    Currently, 40 CFR 63.361 defines an ``Operating day'' as ``any day 
that a facility is engaged in a sterilization operation.'' The EPA is 
proposing to define an ``operating day'' as ``any day that an affected 
source is engaged in a sterilization operation'' for the following 
reason. ``Sterilization operation'' is defined in 40 CFR 63.361 as 
``any time when EtO is removed from the sterilization chamber through 
the SCV or the CEV, when EtO is removed from the aeration room through 
the aeration room vent, when EtO is stored within the building, when 
EtO is dispensed from a container to a chamber, when material is moved 
from sterilization to aeration, or when materials are handled post-
aeration.'' The EPA's intent with this definition was to make sure no 
EtO emissions from sterilization and related processes go unchecked; 
however, one company has indicated that the operating day definition 
may inadvertently include facility operation emission streams from a 
non-operating vent in the compliance determination because the 
definition implies that if any affected source at a facility is engaged 
in a sterilization operation then all affected sources are engaged in a 
sterilization operation, regardless of whether or not they are actually 
in use. As an example, suppose a facility is engaged in a sterilization 
operation, but the aeration room does not contain any sterilized 
material. Because the operating day is currently defined by the 
facility itself being engaged in operation (as opposed to the affected 
source), the ARV (and its control device) would need to be included in 
the compliance analysis even when no aeration is occurring. If this 
example site was using CEMS for compliance, the site would be forced to 
report EtO mass emissions for this ARV, which result from the minimal 
background values from the CEMS, which do not reflect EtO use, and the 
flowrate from the aeration room vent.
    The EPA is proposing to modify the definition of operating day so 
that it applies to when an affected source is engaged in a 
sterilization operation, as opposed to the entire facility, and the EPA 
solicits comment on this proposed modification to the definition 
(Question 14).
b. Definitions of Single-Item Sterilization and Sterilization Operation
    The EPA reviewed the use of the terms ``container,'' ``EtO non-
cartridge storage media,'' and ``pouch'' within five definitions in 40 
CFR 63.361 and is proposing to modify two of the definitions for 
consistency.
    The definition of ``Sterilization operation'' uses the term 
``container'' to refer to EtO storage vessels. However, in other 
definitions, the different term ``non-cartridge storage media (e.g., 
drums, cylinders)'' is used to refer to EtO storage vessels. For 
example, ``non-cartridge storage media (e.g., drums, cylinders)'' is 
used in the definition of ``EtO dispensing''. In order to be consistent 
in referring to EtO storage vessels, the EPA is proposing to change the 
definition of ``Sterilization operation'' by replacing the term 
``container'' with ``non-cartridge storage media'' to read as ``any 
time when EtO is removed from the sterilization chamber through the SCV 
or the CEV, when EtO is removed from the aeration room through the ARV, 
when EtO is stored within the building, when EtO is dispensed from a 
non-cartridge storage media (e.g., drums, cylinders) to a chamber, when 
material is moved from sterilization to aeration, or when materials are 
handled post-aeration.''
    The definition for ``Single-item sterilization'' uses the term 
``pouch'' to refer to the containers used to hold the single items to 
be sterilized; however, other definitions use the different term 
``container (e.g., bags, pouches)'' to refer to a container to hold 
single items. For example, ``container (e.g., bags, pouches)'' is used 
in the definitions of ``Injection room'' and ``Post-injection handling 
of containers.'' For consistency, the EPA is proposing to change the 
definition for ``Single-item sterilization'' by replacing the term 
``pouch'' with ``container'' to read as ``a process in which one or 
more items are placed in a container (e.g., bags, pouches), EtO is 
injected into the container, and the sealed container is placed in a 
vessel to allow sterilization to occur.'' The EPA solicits comment on 
the proposed modifications to these definitions (Question 15).
c. Definition of Indoor EtO Storage
    In the 2024 Final Rule, Group 1 room air emissions, which include 
indoor EtO storage, are subject to either 112(f)(2) or section 112(d) 
standards, both of which require operation in accordance with PTE 
requirements to assure compliance.\34\ 40 CFR 63.361 states, ``Indoor 
EtO storage means the storage of EtO within non-cartridge media (e.g., 
drums, cylinders) inside a sterilization building.'' However, this 
definition does not distinguish between EtO calibration gas cylinders 
that are only being used to evaluate the performance of EtO CEMS and 
are not used for sterilization and the EtO used for sterilization. 
Since promulgation of the 2024 Final Rule, the EPA has been asked to 
clarify whether the definition of indoor EtO storage includes those EtO 
calibration gas cylinders that are being used to evaluate the 
performance of EtO CEMS. The EPA had not intended to include in the 
definition of ``indoor EtO storage'' EtO gas calibrations cylinders, 
which are used for verifying EtO CEMS performance, because properly 
stored and handled cylinders should not leak, and even if the cylinders 
were to leak, the EPA expects any EtO released would be negligible in 
light of the very small amount kept in these cylinders for EtO CEMS 
performance evaluation only. As such, the EPA is proposing to modify 
the definition of ``indoor EtO storage'' to exclude the EtO calibration 
gas cylinders stored or used only to verify the performance of EtO 
CEMS. The EPA proposes to modify the definition of indoor EtO storage 
to state ``Indoor EtO storage means the storage of EtO within non-
cartridge media (e.g., drums, cylinders) inside a sterilization 
building to be used in the sterilization process (excluding EtO storage 
media of calibration gas cylinders that is only used to verify the 
performance of EtO CEMS).'' The EPA solicits comment on this proposed 
modification to the definition (Question 16).
d. EtO CEMS Inlet Time-Sharing
    40 CFR 63.363(e)(1) states that facilities may time-share their EtO 
CEMS provided that, among other things, the measurement points are 
equidistant. Some facilities have provided input that this requirement 
is impractical for systems with many measurement points (particularly 
inlet measurement systems). Similarly, facilities have noted that it 
may be impractical to retrofit these systems to comply with the 
equidistance requirement at 40 CFR 63.363(e)(1)(A). This requirement 
ensured similar response times between sources sharing

[[Page 12727]]

the CEMS; however, the EPA has learned that CEMS manufacturers have 
developed systems that are able to maintain similar response times 
despite different distances in sampling lines, rendering the 
equidistance requirement unnecessary when such systems are used.\68\ 
The EPA therefore proposes to revise the regulatory text in 40 CFR 
63.363(b)(1)(i)(A) \69\ to read ``The measurement points are 
approximately equidistant from the CEMS or the response times are 
approximately the same under the system design'' to account for those 
systems designed to ensure similar response times between shared 
systems.\70\ The EPA solicits comment on this proposed change (Question 
17).
---------------------------------------------------------------------------

    \68\ 89 FR 24090 (Apr. 5, 2024).
    \69\ Redesignated to 40 CFR 63.353(e)(1)(i) in this 
reconsideration. See the redline strikeout of the regulatory text in 
the docket for this rule.
    \70\ See PS-19 in Appendix B to 40 CFR part 60 for response time 
testing requirements.
---------------------------------------------------------------------------

e. Requirements for Flow Rate Monitors in EtO CEMS Applications
    The 2024 Final Rule requires the use of a flow rate monitor to 
demonstrate compliance with the use of EtO CEMS. Flow rate monitoring 
is an essential component of EtO CEMS. However, in the 2024 Final Rule, 
the EPA incorporated two different sets of requirements for flow rate 
monitors as an oversight. At 40 CFR 63.364(g)(3), the EPA provided the 
requirements for flow rate monitors that are used to verify the 
performance of PTEs; these requirements are the correct requirements. 
Appendix A to subpart O provides a different and incorrect set of flow 
rate monitoring requirements. The requirements included in Appendix A 
to subpart O were modelled after and referenced those found in Appendix 
B to 40 CFR part 63, subpart UUUUU, which includes requirements 
relating to the monitoring of hydrochloric acid. Sterilization 
facilities do not use hydrochloric acid and as such, these requirements 
are not applicable to the subpart O NESHAP. Because the EPA is 
proposing to rescind the PTE requirements, we propose to update 40 CFR 
63.364(g) to remove references to PTE while retaining the appropriate 
flow rate monitoring requirements, which would be needed should a 
facility choose to utilize CEMS. Additionally, the EPA is proposing 
revisions to Appendix A to replace any reference to the incorrect flow 
rate requirements with references to the updated 40 CFR 63.364(g)(2) to 
ensure that the flow rate monitoring requirements in Appendix A to 
subpart O are appropriate for sterilization facilities. The EPA is also 
proposing to remove additional unnecessary references found in Appendix 
A as a result of this oversight.
    In conjunction with this proposed change, there are several 
sections of the regulatory text within Appendix A to the Commercial 
Sterilization Facilities NESHAP that would change because they would 
become irrelevant. Table 6 includes the sections of each correction, 
the correction that would need to be made should the change discussed 
above be finalized, and the reasoning for the correction
BILLING CODE 6560-50-P

[[Page 12728]]

[GRAPHIC] [TIFF OMITTED] TP17MR26.025

BILLING CODE 6560-50-C
    The EPA solicits comment on the proposal to remove all references 
to 40 CFR part 75 for flow rate monitors within Appendix A to the 
Commercial Sterilization Facilities NESHAP, with references to 40 CFR 
63.364(g)(2), as well as the corrections described in table 6 that 
would result from this change (Question 18).
f. Other Proposed Corrections
    In addition to the proposed amendments described above, the EPA is 
also proposing, and solicits comment on, the following correction to 
add text regarding the timing requirements for RATA testing consistent 
with other performance specifications that was inadvertently omitted 
from the 2024 Final Rule:
     In section 2.2.4.3 of Appendix A to subpart O, add ``RATA 
test runs must be at least 21 minutes in length'' at the end (Question 
19).
    A redline strike-out version of the proposed regulatory language 
for the Commercial Sterilization Facilities NESHAP is available in 
Docket ID No. EPA-HQ-OAR-2019-0178.

F. What technical corrections and amendments to Performance 
Specification 19 are we proposing, and what is the rationale for those 
actions?

    The 2024 Final Rule introduced a new performance specification for 
EtO CEMS (PS 19) and an associated quality assurance procedure that are 
applicable not just to Commercial Sterilization Facilities but for any 
facility that chooses to continuously monitor its EtO

[[Page 12729]]

emissions. After the publication of the 2024 Final Rule, the EPA 
discovered, through its own internal reassessment of the regulatory 
text as well as through communications with stakeholders, erroneous 
cross-references and typographical errors within PS 19. This action 
addresses the technical errors in PS 19 identified to date by 
stakeholders and the EPA.
1. Technical Corrections for PS 19
    The EPA has identified inadvertent errors in the regulatory text of 
PS 19, including cross-reference and typographical errors. Table 7 
includes the sections of each identified error, the corrections being 
made by this action, and the reasoning for the corrections.
[GRAPHIC] [TIFF OMITTED] TP17MR26.026

    This action proposes technical corrections to clarify language in 
the regulatory text that was erroneously included (or in some cases, 
erroneously omitted). First, in section 3.1, the EPA is proposing to 
revise the definition of ``Calibration drift'' to delete everything 
from ``Calibration Span'' to the end of section 3.1. Then, the Agency 
is proposing to add section 3.2 to define ``Calibration Span'', which 
includes all the text that was deleted from section 3.1. Second, in 
section 3.18, the EPA is proposing to revise the definition of 
``Standard addition'' by adding ``to the actual measurement path or'' 
between ``dynamically)'' and ``measured'' to clarify that the term 
applies to both the measurement path and the measured sample gas 
stream. Also, through this correction, the definition of ``Standard 
addition'' will be consistent with how that term is defined in PS 18, 
which was the model for PS 19. A redline strike-out version of the 
proposed corrected regulatory language for PS 19 is available in Docket 
ID No. EPA-HQ-OAR-2019-0178.
2. Technical Corrections for PS 19 Appendix A
    Following signature of the 2024 Final Rule, the EPA identified 
inadvertent errors in the regulatory text of PS 19 Appendix A, 
including cross-reference and table designation errors. In section 
8.1.4, the Agency is proposing to replace ``section 8.2 or 8.3'' with 
``section 8.2'' to correct an inadvertent cross-reference error. In 
section 13.0, the Agency is proposing to redesignate ``Table A13--1'' 
to ``Table A1''. A redline strike-out version of the proposed corrected 
regulatory language for PS 19 Appendix A is available in Docket ID No. 
EPA-HQ-OAR-2019-0178.
3. Technical Corrections for PS 19 Appendix B
    Following signature of the 2024 Final Rule, the EPA identified 
inadvertent errors in the regulatory text of PS 19 Appendix B, 
including cross-reference and typographical errors. Table 8 includes 
the sections of each identified error, the proposed corrections being 
made by this action, and the reasoning for the proposed corrections.
BILLING CODE 6560-50-P

[[Page 12730]]

[GRAPHIC] [TIFF OMITTED] TP17MR26.027


[[Page 12731]]


[GRAPHIC] [TIFF OMITTED] TP17MR26.028

    A redline strike-out version of the proposed corrected regulatory 
language for PS 19 Appendix B is available in Docket ID No. EPA-HQ-OAR-
2019-0178.
4. Technical Corrections for Procedure 7 of 40 CFR 60 Appendix F
    Following signature of the 2024 Final Rule, the EPA identified 
inadvertent errors in the regulatory text of Procedure 7 of 40 CFR 60 
Appendix F, including cross-reference, section designation, and 
typographical errors. Table 9 includes the section of each identified 
error, the corrections being proposed in this action, and the reasoning 
for the corrections.
[GRAPHIC] [TIFF OMITTED] TP17MR26.029


[[Page 12732]]


BILLING CODE 6560-50-C
    This action also proposes technical corrections to clarify language 
in the regulatory text that was erroneously included. First, in section 
5.1.3.2, the EPA is proposing to delete ``5.2.3.3 Calculate results as 
described in section 6.3.'' and add a new section 5.1.3.3 which will 
read ``Calculate results as described in section 6.3''. This language 
was clearly meant to be its own section, but due to an inadvertent 
typographical error, it was made part of section 5.1.3.2. Second, in 
section 7.1.1, the EPA is proposing to delete '' 7.1.2 If the accuracy 
audit results show the CEMS to be out-of-control, you must report both 
the audit results showing the CEMS to be out-of-control and the results 
of the audit following corrective action showing the CEMS to be 
operating within specifications.'', as this language is already present 
in section 7.1.2.
    A redline strike-out version of the proposed corrected regulatory 
language for Procedure 7 is available in Docket ID No. EPA-HQ-OAR-2019-
0178.

G. What compliance dates are we proposing, and what is the rationale 
for the proposed compliance dates?

    The 2024 Final Rule includes standards promulgated under CAA 
section 112(d)(2) and (3), (d)(5), and (d)(6), and existing sources 
must comply within three years, the maximum time allowed under CAA 
section 112(i)(3)(A).\71\ In addition, the 2024 Final Rule includes 
more stringent risk-based standards for some affected sources pursuant 
to CAA section 112(f)(2), and existing sources must comply within two 
years, as required by CAA section 112(f)(4).\72\ Accordingly, under the 
2024 Final Rule, the compliance deadlines for existing sources are 
April 6, 2026, for the section 112(f)(2) standards, and April 5, 2027, 
for the section 112(d) standards. For all standards, new sources must 
comply by the effective date of the 2024 Final Rule (i.e., April 5, 
2024) or upon startup, whichever is later. See 40 CFR 63.360(j) and 
tables 1 through 5 to subpart O of part 63; see also CAA sections 
112(i)(3)(A) and 112(f)(4).
---------------------------------------------------------------------------

    \71\ 89 FR 24090 (Apr. 5, 2024).
    \72\ Id.
---------------------------------------------------------------------------

    As discussed in section III.A of this document, the EPA is 
proposing to remove the CAA section 112(f)(2) standards. As a result, 
existing sources that currently are subject to both section 112(d) 
standards and section 112(f)(2) standards promulgated in the 2024 Final 
Rule would only be subject to the applicable section 112(d) standards. 
As mentioned above, the compliance deadline for section 112(d) 
standards for existing sources is April 5, 2027.\73\ For new sources 
(as defined under the 2024 Final Rule) subject to section 112(f)(2) 
standards that have already started up, because the section 112(f)(2) 
standards in the 2024 Final Rule are more stringent than section 112(d) 
standards (with several that are the same as section 112(d)(6) 
standards), compliance with section 112(f)(2) standards would also mean 
compliance with section 112(d) standards. For the reasons stated above, 
the EPA believes that sources can still meet the current compliance 
deadlines with the removal of the section 112(f)(2) standards.
---------------------------------------------------------------------------

    \73\ As discussed in section II.D of this preamble, this 
compliance deadline is now extended to April 5, 2029, for facilities 
granted a two-year waiver via Presidential Proclamation, 
``Regulatory Relief for Certain Stationary Sources to Promote 
American Security With Respect to Sterile Medical Equipment,'' 90 FR 
34747 (July 23, 2025).
---------------------------------------------------------------------------

    In addition to proposing removal of the CAA section 112(f)(2) 
standards, the EPA is proposing to amend the section 112(d)(6) standard 
for new ARVs at facilities where EtO usage is at least 10 tpy. For the 
reasons explained in section III.B, the EPA is proposing to change this 
standard from 99.9 percent reduction to 99.6 percent reduction. Because 
new ARVs (as defined in the 2024 Final Rule) that already started up 
are currently operating under the more stringent 99.9 percent reduction 
standard in the 2024 Final Rule, they are already meeting the less 
stringent proposed standard of 99.6 percent reduction. The EPA does not 
foresee problems with new ARVs (as defined by the 2024 Final Rule) at 
facilities where EtO usage is at least 10 tpy complying with the 
proposed revised standard by the current deadlines in the 2024 Final 
Rule (i.e., upon startup or by April 5, 2024, whichever is later).\74\
---------------------------------------------------------------------------

    \74\ Supra n.10.
---------------------------------------------------------------------------

    The EPA considered whether the proposed changes to the methods for 
demonstrating compliance could impact facilities' ability to 
demonstrate compliance with existing source standards under the current 
deadline. This reconsideration proposes to remove the requirement that 
CEMS be used for demonstrating compliance; thus, industry will not need 
time to comply with this requirement. However, this change represents a 
return to the compliance demonstration practice currently used by 
industry. While the EPA is proposing to amend the specific requirements 
and details of the parametric monitoring and performance testing 
approach, these changes do not represent a substantial change in 
methods and should not present a substantial burden to industry. As 
such, the EPA does not anticipate these changes to need more time than 
provided by the compliance deadline already in place.
    For these reasons, the EPA is proposing to retain the compliance 
dates for existing and new sources in 40 CFR 63.360 and in tables 1 to 
5 to subpart O of part 63. The EPA is soliciting comment on compliance 
deadlines (Question 20).

IV. Severability

    This proposed rule contains several discrete components, which the 
EPA views as severable as a practical matter--i.e., they are 
functionally independent and operate in practice independently of the 
other components. These discrete components are generally delineated by 
the section headings and subheadings of this preamble. For example, the 
proposed rescission of the risk-based standards based on the best 
reading of CAA section 112(f)(2) is severable from the proposed 
revision to the new source standard for ARV at facilities using at 
least 10 tpy based on EPA's reconsideration of this standard under 
section 112(d)(6). The final rule also includes other revisions to the 
Sterilization Facilities NESHAP that generally function independently 
of one another (e.g., revisions to the compliance demonstration 
requirements to allow facilities to choose between parametric 
monitoring or using CEMS, rescission of the requirement to use PTE to 
ensure complete capture of EtO).

V. Summary of Cost, Environmental, and Economic Impacts

A. What are the affected sources?

    There are 89 facilities in the Commercial Sterilization Facilities 
source category that are currently operating. A complete list of 
facilities that are currently subject to the NESHAP is available in the 
document ``2024 Facility List,'' which is available in the docket for 
this rulemaking.

B. What are the air quality impacts?

    For the standards that the EPA is proposing, there is an estimated 
EtO emissions increase of 7.8 tpy for the total source category because 
of the removal of CAA section 112(f)(2) standards and revision of the 
section 112(d)(6) standards for new ARVs at facilities where EtO use is 
at least 10 tpy. See the memorandum titled Regulatory Impact Analysis 
for the Proposed Reconsideration of the 2024 National Emission 
Standards for Hazardous Air Pollutants: Ethylene

[[Page 12733]]

Oxide Commercial Sterilization and Fumigation Operations, which is 
available in the docket for this rulemaking.

C. What are the cost impacts?

    The nationwide costs of the proposed amendments are presented in 
table 10 of this preamble. As described in this preamble, the EPA is 
removing the CAA section 112(f)(2) standards and revising the section 
112(d)(6) standards for new ARVs at facilities where EtO use is at 
least 10 tpy. As a result, industry will see overall cost savings in 
comparison to the 2024 Final Rule. The total savings for capital 
investment for the proposal is estimated to be about $280 million in 
2024 dollars. The Agency estimates the total annual compliance cost 
savings of the proposal, compared to the estimated costs associated 
with the 2024 Final Rule, to be approximately $50 million.
[GRAPHIC] [TIFF OMITTED] TP17MR26.030

D. What are the economic impacts?

    The present value (PV) of the estimated compliance cost savings 
from 2026 to 2045 for the proposed reconsideration is $630 million in 
2024 dollars, discounted at a 3 percent rate. The equivalent annualized 
value (EAV) of the estimated cost savings is $43 million, using a 3 
percent discount rate. Using a 7 percent discount rate, the PV and EAV 
of the cost savings are estimated to be $510 million and $48 million, 
respectively. This proposed reconsideration is estimated to result in 
net compliance cost savings for the impacted source category.
    The EPA conducted economic impact analyses for this proposal, as 
detailed in the memorandum titled Regulatory Impact Analysis for the 
Proposed Reconsideration of the 2024 National Emission Standards for 
Hazardous Air Pollutants: Ethylene Oxide Commercial Sterilization and 
Fumigation Operations, which is available in the docket for this 
action. For the proposed reconsideration, the EPA performed a screening 
analysis which compared facility-level annualized compliance costs to 
annual revenues of the ultimate owner of the facility (or facilities), 
known as the ultimate parent company. These cost-to-sales ratios (CSRs) 
underpin the ``sales test'' methodology the EPA uses to assess small 
business impacts for a rulemaking.
    There are 89 facilities, owned by 49 ultimate parent companies, 
affected by the proposed amendments. Of these 89 facilities, 23 
facilities (26 percent), are owned by a total 19 ultimate parent 
companies that are small entities. The Agency calculated the CSRs for 
all affected parent companies to assess the magnitude of the costs of 
the proposed amendments and determine whether there is potential for 
significant impacts on small entities. As shown in table 10, this 
proposed reconsideration does incur cost increases related to one-time 
costs for cycle revalidations and recordkeeping and reporting costs. 
However, these cost increases are less than the net cost savings for 16 
of the affected 19 small entities. The 16 small entities estimated to 
experience net cost savings under this proposed reconsideration are 
expected to have lower CSRs relative to the 2024 Final Rule. Of the 3 
small entities projected to incur additional requirement costs relative 
to 2024 Final Rule, one has an estimated CSR above 3 percent. The 
average annualized cost savings for small entities is about $0.68 
million and about $0.35 million for the remaining entities. The average 
annual sales for the 19 small entities is $38 million, while the 
remaining 30 entities have average annual sales of $15 billion. 
Relative to the 2024 Final Rule, the average CSR for all firms 
decreased by 4.3 percent, down to approximately 3.8 percent. Similarly, 
the CSRs for large and small firms decreased by 0.26 percent (down to 
approximately 0.11 percent) and by 10.6 percent (down to approximately 
10 percent), respectively. Large firms incur most of the total costs 
estimated for the proposed rule and they incur higher total annual 
costs per firm on average than small firms. However, when estimated 
costs are examined relative to revenues, large firms are less affected 
by the proposed rule than small firms.
    EtO sterilization services are a critical input in the provision of 
safe medical devices. According to the U.S. Food and Drug 
Administration (FDA), more than 20 billion medical devices used in the 
U.S. every year are sterilized with EtO, accounting for approximately 
50 percent of medical devices that require sterilization. In the 2024 
Final Rule regulatory impact analysis (RIA), the industry profile in 
section 2 discusses the role of EtO in providing a significant number 
of healthcare products to the

[[Page 12734]]

public and why it is often the only sterilization method that can be 
used for a wide variety of common medical devices.\75\ The EPA was not 
able to quantitatively assess potential market impacts for this 
proposed rule. However, it is likely that this proposed reconsideration 
would reduce the risk of capacity constraints in the sterilization 
sector. In the 2024 Final Rule RIA, the EPA examined a scenario where 
the 2024 Final Rule requirements lead to facilities needing to 
temporarily reduce their capacity and thus lose revenue during that 
time. The EPA requests comment on whether the proposed standards would 
result in a similar risk of capacity constraints in the sterilization 
sector (Question 21). To the extent that this proposed reconsideration 
avoids the need for facilities to reduce capacity, the cost savings of 
this action are estimated to be higher than the estimates of the 
examined scenario in the 2024 Final Rule RIA.
---------------------------------------------------------------------------

    \75\ U.S. EPA. (2024). Regulatory Impact Analysis for the Final 
National Emission Standards for Hazardous Air Pollutants: Ethylene 
Oxide Commercial Sterilization and Fumigation Operations. Available 
at: https://www.regulations.gov/document/EPA-HQ-OAR-2019-0178-1557.
---------------------------------------------------------------------------

E. What are the benefits?

    Being unable to adequately supply sterilized medical equipment to 
our medical personnel to safely treat patients in hospitals, operating 
rooms, and other medical facilities would undermine our national 
security. This rule, if finalized, would help ensure a secure medical 
supply chain as it would decrease the probability of commercial 
sterilizers shuttering and the United States having to rely on other 
countries to sterilize medical devices. While the EPA acknowledges 
significant national security benefits if this rule is finalized, the 
Agency is unable to monetize these national security benefits 
Consistent with longstanding practice, the EPA did not monetize the 
foregone benefits from the estimated emission changes in HAP associated 
with this proposed reconsideration. The EPA currently does not have 
sufficient methods to monetize benefits associated with HAP. This does 
not imply that there are no impacts associated with the EtO emission 
increases estimated for this proposed rule. Non-monetized health 
disbenefits are expected under this proposed reconsideration from 
estimated increases of 7.8 tons of EtO annually relative to the 2024 
Final Rule. A qualitative discussion of the health effects associated 
with EtO exposure is provided in the memorandum titled Regulatory 
Impact Analysis for the Proposed Reconsideration of the 2024 National 
Emission Standards for Hazardous Air Pollutants: Ethylene Oxide 
Commercial Sterilization and Fumigation Operations, which is available 
in the docket for this rulemaking.

VI. Request for Comments

    We solicit comment on all aspects of this proposed action. In 
addition to general comments on this proposed action, we are also 
interested in additional data that may improve the analyses.
    Throughout this proposal, the EPA is soliciting comment on numerous 
aspects of the proposed rule. The EPA has indexed each comment 
solicitation with an identifier (e.g., ``Question 1, Question 2, . . .) 
to provide a consistent framework for effective and efficient provision 
of comments. Accordingly, we ask that commenters include the 
corresponding identifier when providing comments relevant to that 
comment solicitation. We ask that commenters include the identifier in 
either a heading, or within the text of each comment (e.g., ``In 
response to Question 1, . . .'') to make clear which comment 
solicitation is being addressed. Below, we list the questions for which 
the EPA invites comment.
    Question #1: Has the 2024 Final Rule and underlying interpretations 
generated reliance interests and, if so, how should the EPA consider 
them in any final action?
    Question #2: Should the EPA rescind the standards set under CAA 
section 112(f)(2) in the 2024 Final Rule, as proposed, based on the 
proposed finding that the discretionary second risk review conducted as 
part of the 2024 Final Rule was not authorized under the CAA?
    Question #3: Is there new information that could be used in dose-
response modeling, such as epidemiological studies of cancer in humans 
exposed to EtO?
    Question #4: Is there any new information relevant to dose-response 
model selection such as consideration of statistical analyses, visual 
model fit, or biological plausibility?
    Question #5: Is there new information related to human exposure to 
EtO, including information on occupational, smoking, background or 
endogenous exposures that may be relevant to estimating the dose-
response relationship of EtO carcinogenicity?
    Question #6: Is there additional information on the comments of the 
2016 IRIS value provided by commenters in the context of the more 
recent proposed CMAS NESHAP (January 22, 2025) (see Docket ID EPA-HQ-
OAR-2024-0303, comment numbers 0060, 0061, 0068, 0076, and 0079)?
    Question #7: Should the EPA modify the emission reductions levels 
for new ARVs at facilities where EtO use is at least 10 tpy from 99.9 
to 99.6 percent reduction, as proposed?
    Question #8: Should the EPA consider manufacturer guarantee levels 
of EtO reduction for ARVs, and if so, what are these levels?
    Question #9: Should facilities have the option of using either 
parametric monitoring and performance testing or CEMS to demonstrate 
initial and continuous compliance with the Commercial Sterilization 
Facilities NESHAP, as proposed?
    Question #10: Should the EPA finalize the proposed changes to 
performance testing, parametric monitoring, and reporting requirements 
as proposed?
    Question #11: Is PTE cost effective and feasible?
    Question #12: Should the EPA not be allowed to treat unregulated 
sources of regulated pollutants the same as unregulated pollutants?
    Question #13: Should the EPA remove PTE requirements?
    Question #14: Should the EPA modify the definition of ``Operating 
day'' so that it applies to when an affected source is engaged in a 
sterilization operation, as opposed to the entire facility, as 
proposed?
    Question #15: Should the EPA modify the definitions of 
``Sterilization operation'' and ``Single-item sterilization'' be 
modified as proposed?
    Question #16: Should the EPA modify the definition of ``Indoor EtO 
storage'' to clarify that EtO storage media of calibration gas 
cylinders that is only used to verify the performance of EtO CEMS is 
excluded, as proposed?
    Question #17: Should the EPA modify 40 CFR 63.363(b)(1) to indicate 
that CEMS measurement points do not need to be equidistant so long as 
the response times are similar, as proposed?
    Question #18: Should the EPA remove all references to 40 CFR part 
75 for flow rate monitors within Appendix A to the Commercial 
Sterilization Facilities NESHAP and should we make the corrections 
described in table 6 be made, as proposed?
    Question #19: Should the EPA add the phrase ``RATA test runs must 
be at least 21 minutes in length'' to the end of section 2.2.4.3 of 
Appendix A to subpart O, as proposed?
    Question #20: Should the EPA retain the compliance deadlines 
promulgated

[[Page 12735]]

in the 2024 Final Rule for the section 112(d) standards as proposed?
    Question #21: Would the proposed standards result in a similar risk 
of capacity constraints as the 2024 Final Rule in the sterilization 
sector?

VII. Statutory and Executive Order Reviews

A. Executive Order 12866: Regulatory Planning and Review and Executive 
Order 13563: Improving Regulation and Regulatory Review

    This action is a significant regulatory action and therefore, the 
EPA submitted this action to the Office of Management and Budget (OMB) 
for Executive Order 12866 review. Any changes made in response to E.O 
12866 review have been documented in the docket. The EPA has prepared 
an analysis of the potential costs and benefits associated with this 
action. This analysis, Regulatory Impact Analysis for the Proposed 
Reconsideration of the 2024 National Emission Standards for Hazardous 
Air Pollutants: Ethylene Oxide Commercial Sterilization and Fumigation 
Operations, is available in the docket. A summary of the costs and 
economic impacts is included in section IV of this preamble.

B. Executive Order 14192: Unleashing Prosperity Through Deregulation

    This action is expected to be an Executive Order 14192 deregulatory 
action. Details on the estimated cost savings of this proposed rule can 
be found in the EPA's analysis of the potential costs and benefits 
associated with this action.

C. Paperwork Reduction Act (PRA)

    The information collection activities in this proposed rule have 
been submitted for approval to OMB under the PRA. The information 
collection request (ICR) document that the EPA prepared has been 
assigned EPA ICR number 1666.12. You can find a copy of the ICR in the 
docket for this rulemaking, and it is briefly summarized here.
    The EPA is proposing amendments that change the reporting and 
recordkeeping requirements for several emission sources at commercial 
sterilization facilities (e.g., SCV, ARV, CEV and room air emissions). 
This information would be collected to assure compliance with 40 CFR 
part 63, subpart O.
    Respondents/affected entities: Owners or operators of commercial 
sterilization facilities.
    Respondent's obligation to respond: Mandatory (40 CFR part 63, 
subpart O).
    Estimated number of respondents: 89 facilities.
    Frequency of response: Quarterly, or annual. Responses include 
monitoring plan, notification of compliance status reports, performance 
test reports and quarterly compliance reports.
    Total estimated burden: 24,077 hours (per year) for the responding 
facilities and 2,541 hours (per year) for the Agency. Burden is defined 
at 5 CFR 1320.3(b).
    Total estimated cost: $6,883,047 (per year), which includes 
$4,529,143 annualized capital and operation and maintenance costs for 
the responding facilities.
    An Agency may not conduct or sponsor, and a person is not required 
to respond to, a collection of information unless it displays a 
currently valid OMB control number. The OMB control numbers for the 
EPA's regulations in 40 CFR are listed in 40 CFR part 9.
    Submit your comments on the Agency's need for this information, the 
accuracy of the provided burden estimates and any suggested methods for 
minimizing respondent burden to the EPA using the docket identified at 
the beginning of this rule. The EPA will respond to any ICR-related 
comments in the final rule. You may also send your ICR-related comments 
to OMB's Office of Information and Regulatory Affairs using the 
interface at www.reginfo.gov/public/do/PRAMain. Find this information 
collection by selecting ``Currently under Review--Open for Public 
Comments'' or by using the search function. OMB must receive comments 
no later than April 16, 2026.

D. Regulatory Flexibility Act (RFA)

    The EPA certifies that this action will not have a significant 
economic impact on a substantial number of small entities under the 
RFA. In making this determination, the EPA concludes that the impact of 
concern for this rule is any adverse economic impact on small entities 
and that the Agency is certifying that this rule will not have a 
significant economic impact on a substantial number of small entities 
because the rule relieves regulatory burden on the small entities 
subject to the rule. This proposed action would lead to reduction in 
EAV of costs over the 2026 to 2046 timeframe of about $43 and $48 
million per year at discount rates of 3 percent and 7 percent, 
respectively. The average annualized cost savings for small entities is 
about $0.68 million and about $0.35 million for the remaining entities. 
For a more detailed analysis, please see the document Regulatory Impact 
Analysis for the Proposed Reconsideration of the 2024 National Emission 
Standards for Hazardous Air Pollutants: Ethylene Oxide Commercial 
Sterilization and Fumigation Operations available in the docket for 
this rule.

E. Unfunded Mandates Reform Act (UMRA)

    This action does not contain an unfunded mandate of $100 million or 
more as described in UMRA, 2 U.S.C. 1531-1538, and does not 
significantly or uniquely affect small governments. The action imposes 
no enforceable duty on any state, local or Tribal government.

F. Executive Order 13132: Federalism

    This action does not have federalism implications. It will not have 
substantial direct effects on the States, on the relationship between 
the national government and the States or on the distribution of power 
and responsibilities among the various levels of government.

G. Executive Order 13175: Consultation and Coordination With Indian 
Tribal Governments

    This action does not have tribal implications as specified in 
Executive Order 13175. None of the commercial sterilization facilities 
that have been identified as being affected by this action are owned or 
operated by Tribal governments or located within Tribal lands. Thus, 
Executive Order 13175 does not apply to this action.

H. Executive Order 13045: Protection of Children From Environmental 
Health Risks and Safety Risks

    Executive Order 13045 directs federal agencies to include an 
evaluation of the health and safety effects of the planned regulation 
on children in federal health and safety standards and explain why the 
regulation is preferable to potentially effective and reasonably 
feasible alternatives. This action is subject to Executive Order 13045 
because it is a significant regulatory action under section 3(f)(1) of 
Executive Order 12866, and the EPA believes that the environmental 
health and safety risk addressed by this action may have a 
disproportionate effect on children. The environmental health and 
safety risks addressed by this action present a disproportionate risk 
to children due to EtO being mutagenic (i.e., it can damage DNA).
    The EPA did not conduct a new analysis of children's environmental 
health for this action. For details on children's health and the impact 
of the CAA section 112(d) standards, please see the Executive Order 
13045 discussion and tables 17 and 18 in the 2024 Final Rule (89 FR 
24090).

[[Page 12736]]

    This action is preferred over other regulatory options analyzed 
because, while it removes the CAA 112(f)(2) standards to better comply 
with the text and structure of the applicable statutory language (see 
section III.A), it retains the first-time standards promulgated in the 
2024 Final Rule under CAA sections 112(d)(2), (3) and (5) for emission 
sources that were unregulated prior to the 2024 Final Rule. These 
standards will continue to apply and protect children's health.
    Furthermore, the EPA's Policy on Children's Health applies to this 
action. For details on children's health and the impact of the CAA 
section 112(d) standards, please see the discussion in the 2024 Final 
Rule (89 FR 24090).

I. Executive Order 13211: Actions Concerning Regulations That 
Significantly Affect Energy Supply, Distribution, or Use

    This action is not a ``significant energy action'' because it is 
not likely to have a significant adverse effect on the supply, 
distribution or use of energy. The overall energy impact of this rule 
should be minimal for commercial sterilization facilities and their 
parent companies.

J. National Technology Transfer and Advancement Act (NTTAA)

    The NTTAA requires the EPA to use voluntary consensus standards 
(VCS) in addition to EPA methods in regulatory activities unless doing 
so would be inconsistent with applicable law or otherwise 
impracticable. VCS are technical documents, such as test methods, that 
are developed or adopted by VCS bodies using procedures that ensure 
that the standards development process is open to all interested 
parties. VCS bodies are generally private sector, not-for-profit 
entities such as the American Society for Testing and Materials (ASTM).
    The EPA searched the Enhanced NSSN Database managed by the American 
National Standards Institute (ANSI) for VCS that could be used in the 
National Emission Standards for Hazardous Air Pollutants for Ethylene 
Oxide Emissions Standards for Sterilization Facilities. The EPA also 
contacted VCS organizations and accessed and searched their databases. 
While the EPA has made a reasonable effort to identify and evaluate 
potentially practical VCS, the findings do not necessarily represent 
all potential alternative standards which may exist.
    Searches were conducted for: EPA Methods 204 and 205 of 40 CFR part 
51, Appendix M; EPA Methods 1, 1A, 2, 2A, 2B, 2C, 2D, 3A, 3B, and 4 of 
40 CFR part 60, Appendix A; and, EPA Methods 301 and 320 of 40 CFR part 
63, Appendix A. The EPA found no VCS are acceptable alternatives for 
EPA Methods 1, 1A, 2, 2A, 2B, 2C, 2D, 3A, 4, 204, 205, and 301. The EPA 
found no acceptable alternative VCS for EPA Methods 1, 1A, 2, 2A, 2B, 
2C, 2D, 3A, 4, 204, 205, and 301.
    The proposed rule continues to include one VCS as an alternative to 
EPA Method 3B for the purposes of this rule. The manual methods in 
ANSI/ASME PTC 19-10-1981 Part 10, ``Flue and Exhaust Gas Analyses'' 
(2010 version) are acceptable alternatives to EPA Method 3B to analyze 
oxygen and carbon dioxide concentrations in the stack gas. The 
instrumental methods in the voluntary consensus standard ANSI/ASME PTC 
19-10-1981 Part 10, ``Flue and Exhaust Gas Analyses'' (2010 version) 
are not acceptable alternatives to EPA Method 3B.
    The proposed rule continues to include one VCS as an alternative to 
EPA Method 320 for the purposes of this rule. The VCS ASTM D6348-12 
(2020), ``Determination of Gaseous Compounds by Extractive Direct 
Interface Fourier Transform (FTIR) Spectroscopy'' is an acceptable 
alternative to EPA Method 320 with caveats requiring inclusion of 
selected annexes to the standard as mandatory. When using ASTM D6348-
12(2020), the following conditions must be met:
    (1) The test plan preparation and implementation in the Annexes to 
ASTM D 6348-12 (R2020), sections A1 through A8 are mandatory; and
    (2) In ASTM D6348-12 (R2020) Annex A5 (Analyte Spiking Technique), 
the percent (%) R must be determined for each target analyte (equation 
A5.5). For the test data to be acceptable for a compound, %R must be 
70% <= R <= 130%. If the %R value does not meet this criterion for a 
target compound, the test data is not acceptable for that compound and 
the test must be repeated for that analyte (i.e., the sampling and/or 
analytical procedure should be adjusted before a retest). The %R value 
for each compound must be reported in the test report, and all field 
measurements must be corrected with the calculated %R value for that 
compound by using equation 1 to this paragraph:

(eq. 1) Reported Results = ((Measured Concentration in Stack))/(%R) x 
100

    According to 40 CFR 63.7(f) and 40 CFR 63.8(f) of subpart A of the 
general provisions, a source may apply to the EPA to use alternative 
test methods or alternative monitoring requirements in place of any 
required testing methods, performance specifications or procedures in 
the final rule or any amendments. The EPA welcomes comments on this 
aspect of the proposed rulemaking and, specifically, invites the public 
to identify potentially applicable VCS and to explain why such 
standards should be used in this regulation.

List of Subjects in 40 CFR Part 63

    Environmental protection, Air pollution control, Hazardous 
substances, Reporting and recordkeeping requirements.

Lee Zeldin,
Administrator.
[FR Doc. 2026-05167 Filed 3-16-26; 8:45 am]
BILLING CODE 6560-50-P